FHIR Release 3 (STU)
TerminologyThis page is part of the FHIR Specification (v3.0.2: STU 3). The current version which supercedes this version is 5.0.0. For a full list of available versions, see the Directory of published versions 
. Page versions: R4 R3
Vocabulary  Work Group | Maturity Level: N/A | External | Use Context: Any |
This value set (http://hl7.org/fhir/ValueSet/v3-ObservationType) is defined as part of HL7 v3. Related FHIR content: ObservationType.
Summary
| Defining URL: | http://hl7.org/fhir/ValueSet/v3-ObservationType |
| Name: | ObservationType |
| Definition: | Identifies the kinds of observations that can be performed |
| OID: | 2.16.840.1.113883.1.11.16226 (for OID based terminology systems) |
| Source Resource | XML / JSON |
This value set is not currently used
This value set includes codes from the following code systems:
http://hl7.org/fhir/v3/ActCode where concept is-a _ObservationTypehttp://loinc.org
This expansion generated 19 Apr 2017
This value set has >1000 codes in it. In order to keep the publication size manageable, only a selection (1000 codes) of the whole set of codes is shown
| Code | System | Display | Definition |
| _ObservationType | http://hl7.org/fhir/v3/ActCode | ObservationType | Identifies the kinds of observations that can be performed |
| _ActSpecObsCode | http://hl7.org/fhir/v3/ActCode | ActSpecObsCode | Identifies the type of observation that is made about a specimen that may affect its processing, analysis or further result interpretation |
| ARTBLD | http://hl7.org/fhir/v3/ActCode | ActSpecObsArtBldCode | Describes the artificial blood identifier that is associated with the specimen. |
| DILUTION | http://hl7.org/fhir/v3/ActCode | ActSpecObsDilutionCode | An observation that reports the dilution of a sample. |
| AUTO-HIGH | http://hl7.org/fhir/v3/ActCode | Auto-High Dilution | The dilution of a sample performed by automated equipment. The value is specified by the equipment |
| AUTO-LOW | http://hl7.org/fhir/v3/ActCode | Auto-Low Dilution | The dilution of a sample performed by automated equipment. The value is specified by the equipment |
| PRE | http://hl7.org/fhir/v3/ActCode | Pre-Dilution | The dilution of the specimen made prior to being loaded onto analytical equipment |
| RERUN | http://hl7.org/fhir/v3/ActCode | Rerun Dilution | The value of the dilution of a sample after it had been analyzed at a prior dilution value |
| EVNFCTS | http://hl7.org/fhir/v3/ActCode | ActSpecObsEvntfctsCode | Domain provides codes that qualify the ActLabObsEnvfctsCode domain. (Environmental Factors) |
| INTFR | http://hl7.org/fhir/v3/ActCode | ActSpecObsInterferenceCode | An observation that relates to factors that may potentially cause interference with the observation |
| FIBRIN | http://hl7.org/fhir/v3/ActCode | Fibrin | The Fibrin Index of the specimen. In the case of only differentiating between Absent and Present, recommend using 0 and 1 |
| HEMOLYSIS | http://hl7.org/fhir/v3/ActCode | Hemolysis | An observation of the hemolysis index of the specimen in g/L |
| ICTERUS | http://hl7.org/fhir/v3/ActCode | Icterus | An observation that describes the icterus index of the specimen. It is recommended to use mMol/L of bilirubin |
| LIPEMIA | http://hl7.org/fhir/v3/ActCode | Lipemia | An observation used to describe the Lipemia Index of the specimen. It is recommended to use the optical turbidity at 600 nm (in absorbance units). |
| VOLUME | http://hl7.org/fhir/v3/ActCode | ActSpecObsVolumeCode | An observation that reports the volume of a sample. |
| AVAILABLE | http://hl7.org/fhir/v3/ActCode | Available Volume | The available quantity of specimen. This is the current quantity minus any planned consumption (e.g., tests that are planned) |
| CONSUMPTION | http://hl7.org/fhir/v3/ActCode | Consumption Volume | The quantity of specimen that is used each time the equipment uses this substance |
| CURRENT | http://hl7.org/fhir/v3/ActCode | Current Volume | The current quantity of the specimen, i.e., initial quantity minus what has been actually used. |
| INITIAL | http://hl7.org/fhir/v3/ActCode | Initial Volume | The initial quantity of the specimen in inventory |
| _AnnotationType | http://hl7.org/fhir/v3/ActCode | AnnotationType | AnnotationType |
| _ActPatientAnnotationType | http://hl7.org/fhir/v3/ActCode | ActPatientAnnotationType | Description:Provides a categorization for annotations recorded directly against the patient . |
| ANNDI | http://hl7.org/fhir/v3/ActCode | diagnostic image note | Description:A note that is specific to a patient's diagnostic images, either historical, current or planned. |
| ANNGEN | http://hl7.org/fhir/v3/ActCode | general note | Description:A general or uncategorized note. |
| ANNIMM | http://hl7.org/fhir/v3/ActCode | immunization note | A note that is specific to a patient's immunizations, either historical, current or planned. |
| ANNLAB | http://hl7.org/fhir/v3/ActCode | laboratory note | Description:A note that is specific to a patient's laboratory results, either historical, current or planned. |
| ANNMED | http://hl7.org/fhir/v3/ActCode | medication note | Description:A note that is specific to a patient's medications, either historical, current or planned. |
| _GeneticObservationType | http://hl7.org/fhir/v3/ActCode | GeneticObservationType | Description: None provided |
| GENE | http://hl7.org/fhir/v3/ActCode | gene | Description: A DNA segment that contributes to phenotype/function. In the absence of demonstrated function a gene may be characterized by sequence, transcription or homology |
| _ImmunizationObservationType | http://hl7.org/fhir/v3/ActCode | ImmunizationObservationType | Description: Observation codes which describe characteristics of the immunization material. |
| OBSANTC | http://hl7.org/fhir/v3/ActCode | antigen count | Description: Indicates the valid antigen count. |
| OBSANTV | http://hl7.org/fhir/v3/ActCode | antigen validity | Description: Indicates whether an antigen is valid or invalid. |
| _IndividualCaseSafetyReportType | http://hl7.org/fhir/v3/ActCode | Individual Case Safety Report Type | A code that is used to indicate the type of case safety report received from sender. The current code example reference is from the International Conference on Harmonisation (ICH) Expert Workgroup guideline on Clinical Safety Data Management: Data Elements for Transmission of Individual Case Safety Reports. The unknown/unavailable option allows the transmission of information from a secondary sender where the initial sender did not specify the type of report. Example concepts include: Spontaneous, Report from study, Other. |
| PAT_ADV_EVNT | http://hl7.org/fhir/v3/ActCode | patient adverse event | Indicates that the ICSR is describing problems that a patient experienced after receiving a vaccine product. |
| VAC_PROBLEM | http://hl7.org/fhir/v3/ActCode | vaccine product problem | Indicates that the ICSR is describing a problem with the actual vaccine product such as physical defects (cloudy, particulate matter) or inability to confer immunity. |
| _LOINCObservationActContextAgeType | http://hl7.org/fhir/v3/ActCode | LOINCObservationActContextAgeType | Definition:The set of LOINC codes for the act of determining the period of time that has elapsed since an entity was born or created. |
| 21611-9 | http://hl7.org/fhir/v3/ActCode | age patient qn est | Definition:Estimated age. |
| 21612-7 | http://hl7.org/fhir/v3/ActCode | age patient qn reported | Definition:Reported age. |
| 29553-5 | http://hl7.org/fhir/v3/ActCode | age patient qn calc | Definition:Calculated age. |
| 30525-0 | http://hl7.org/fhir/v3/ActCode | age patient qn definition | Definition:General specification of age with no implied method of determination. |
| 30972-4 | http://hl7.org/fhir/v3/ActCode | age at onset of adverse event | Definition:Age at onset of associated adverse event; no implied method of determination. |
| _MedicationObservationType | http://hl7.org/fhir/v3/ActCode | MedicationObservationType | MedicationObservationType |
| REP_HALF_LIFE | http://hl7.org/fhir/v3/ActCode | representative half-life | Description:This observation represents an 'average' or 'expected' half-life typical of the product. |
| SPLCOATING | http://hl7.org/fhir/v3/ActCode | coating | Definition: A characteristic of an oral solid dosage form of a medicinal product, indicating whether it has one or more coatings such as sugar coating, film coating, or enteric coating. Only coatings to the external surface or the dosage form should be considered (for example, coatings to individual pellets or granules inside a capsule or tablet are excluded from consideration). Constraints: The Observation.value must be a Boolean (BL) with true for the presence or false for the absence of one or more coatings on a solid dosage form. |
| SPLCOLOR | http://hl7.org/fhir/v3/ActCode | color | Definition: A characteristic of an oral solid dosage form of a medicinal product, specifying the color or colors that most predominantly define the appearance of the dose form. SPLCOLOR is not an FDA specification for the actual color of solid dosage forms or the names of colors that can appear in labeling. Constraints: The Observation.value must be a single coded value or a list of multiple coded values, specifying one or more distinct colors that approximate of the color(s) of distinct areas of the solid dosage form, such as the different sides of a tablet or one-part capsule, or the different halves of a two-part capsule. Bands on banded capsules, regardless of the color, are not considered when assigning an SPLCOLOR. Imprints on the dosage form, regardless of their color are not considered when assigning an SPLCOLOR. If more than one color exists on a particular side or half, then the most predominant color on that side or half is recorded. If the gelatin capsule shell is colorless and transparent, use the predominant color of the contents that appears through the colorless and transparent capsule shell. Colors can include: Black;Gray;White;Red;Pink;Purple;Green;Yellow;Orange;Brown;Blue;Turquoise. |
| SPLIMAGE | http://hl7.org/fhir/v3/ActCode | image | Description: A characteristic representing a single file reference that contains two or more views of the same dosage form of the product; in most cases this should represent front and back views of the dosage form, but occasionally additional views might be needed in order to capture all of the important physical characteristics of the dosage form. Any imprint and/or symbol should be clearly identifiable, and the viewer should not normally need to rotate the image in order to read it. Images that are submitted with SPL should be included in the same directory as the SPL file. |
| SPLIMPRINT | http://hl7.org/fhir/v3/ActCode | imprint | Definition: A characteristic of an oral solid dosage form of a medicinal product, specifying the alphanumeric text that appears on the solid dosage form, including text that is embossed, debossed, engraved or printed with ink. The presence of other non-textual distinguishing marks or symbols is recorded by SPLSYMBOL. Examples: Included in SPLIMPRINT are alphanumeric text that appears on the bands of banded capsules and logos and other symbols that can be interpreted as letters or numbers. Constraints: The Observation.value must be of type Character String (ST). Excluded from SPLIMPRINT are internal and external cut-outs in the form of alphanumeric text and the letter 'R' with a circle around it (when referring to a registered trademark) and the letters 'TM' (when referring to a 'trade mark'). To record text, begin on either side or part of the dosage form. Start at the top left and progress as one would normally read a book. Enter a semicolon to show separation between words or line divisions. |
| SPLSCORING | http://hl7.org/fhir/v3/ActCode | scoring | Definition: A characteristic of an oral solid dosage form of a medicinal product, specifying the number of equal pieces that the solid dosage form can be divided into using score line(s). Example: One score line creating two equal pieces is given a value of 2, two parallel score lines creating three equal pieces is given a value of 3. Constraints: Whether three parallel score lines create four equal pieces or two intersecting score lines create two equal pieces using one score line and four equal pieces using both score lines, both have the scoring value of 4. Solid dosage forms that are not scored are given a value of 1. Solid dosage forms that can only be divided into unequal pieces are given a null-value with nullFlavor other (OTH). |
| SPLSHAPE | http://hl7.org/fhir/v3/ActCode | shape | Description: A characteristic of an oral solid dosage form of a medicinal product, specifying the two dimensional representation of the solid dose form, in terms of the outside perimeter of a solid dosage form when the dosage form, resting on a flat surface, is viewed from directly above, including slight rounding of corners. SPLSHAPE does not include embossing, scoring, debossing, or internal cut-outs. SPLSHAPE is independent of the orientation of the imprint and logo. Shapes can include: Triangle (3 sided); Square; Round; Semicircle; Pentagon (5 sided); Diamond; Double circle; Bullet; Hexagon (6 sided); Rectangle; Gear; Capsule; Heptagon (7 sided); Trapezoid; Oval; Clover; Octagon (8 sided); Tear; Freeform. |
| SPLSIZE | http://hl7.org/fhir/v3/ActCode | size | Definition: A characteristic of an oral solid dosage form of a medicinal product, specifying the longest single dimension of the solid dosage form as a physical quantity in the dimension of length (e.g., 3 mm). The length is should be specified in millimeters and should be rounded to the nearest whole millimeter. Example: SPLSIZE for a rectangular shaped tablet is the length and SPLSIZE for a round shaped tablet is the diameter. |
| SPLSYMBOL | http://hl7.org/fhir/v3/ActCode | symbol | Definition: A characteristic of an oral solid dosage form of a medicinal product, to describe whether or not the medicinal product has a mark or symbol appearing on it for easy and definite recognition. Score lines, letters, numbers, and internal and external cut-outs are not considered marks or symbols. See SPLSCORING and SPLIMPRINT for these characteristics. Constraints: The Observation.value must be a Boolean (BL) with <u>true</u> indicating the presence and <u>false</u> for the absence of marks or symbols. Example: |
| _ObservationIssueTriggerCodedObservationType | http://hl7.org/fhir/v3/ActCode | ObservationIssueTriggerCodedObservationType | Distinguishes the kinds of coded observations that could be the trigger for clinical issue detection. These are observations that are not measurable, but instead can be defined with codes. Coded observation types include: Allergy, Intolerance, Medical Condition, Pregnancy status, etc. |
| _CaseTransmissionMode | http://hl7.org/fhir/v3/ActCode | case transmission mode | Code for the mechanism by which disease was acquired by the living subject involved in the public health case. Includes sexually transmitted, airborne, bloodborne, vectorborne, foodborne, zoonotic, nosocomial, mechanical, dermal, congenital, environmental exposure, indeterminate. |
| AIRTRNS | http://hl7.org/fhir/v3/ActCode | airborne transmission | Communication of an agent from a living subject or environmental source to a living subject through indirect contact via oral or nasal inhalation. |
| ANANTRNS | http://hl7.org/fhir/v3/ActCode | animal to animal transmission | Communication of an agent from one animal to another proximate animal. |
| ANHUMTRNS | http://hl7.org/fhir/v3/ActCode | animal to human transmission | Communication of an agent from an animal to a proximate person. |
| BDYFLDTRNS | http://hl7.org/fhir/v3/ActCode | body fluid contact transmission | Communication of an agent from one living subject to another living subject through direct contact with any body fluid. |
| BLDTRNS | http://hl7.org/fhir/v3/ActCode | blood borne transmission | Communication of an agent to a living subject through direct contact with blood or blood products whether the contact with blood is part of a therapeutic procedure or not. |
| DERMTRNS | http://hl7.org/fhir/v3/ActCode | transdermal transmission | Communication of an agent from a living subject or environmental source to a living subject via agent migration through intact skin. |
| ENVTRNS | http://hl7.org/fhir/v3/ActCode | environmental exposure transmission | Communication of an agent from an environmental surface or source to a living subject by direct contact. |
| FECTRNS | http://hl7.org/fhir/v3/ActCode | fecal-oral transmission | Communication of an agent from a living subject or environmental source to a living subject through oral contact with material contaminated by person or animal fecal material. |
| FOMTRNS | http://hl7.org/fhir/v3/ActCode | fomite transmission | Communication of an agent from an non-living material to a living subject through direct contact. |
| FOODTRNS | http://hl7.org/fhir/v3/ActCode | food-borne transmission | Communication of an agent from a food source to a living subject via oral consumption. |
| HUMHUMTRNS | http://hl7.org/fhir/v3/ActCode | human to human transmission | Communication of an agent from a person to a proximate person. |
| INDTRNS | http://hl7.org/fhir/v3/ActCode | indeterminate disease transmission mode | Communication of an agent to a living subject via an undetermined route. |
| LACTTRNS | http://hl7.org/fhir/v3/ActCode | lactation transmission | Communication of an agent from one living subject to another living subject through direct contact with mammalian milk or colostrum. |
| NOSTRNS | http://hl7.org/fhir/v3/ActCode | nosocomial transmission | Communication of an agent from any entity to a living subject while the living subject is in the patient role in a healthcare facility. |
| PARTRNS | http://hl7.org/fhir/v3/ActCode | parenteral transmission | Communication of an agent from a living subject or environmental source to a living subject where the acquisition of the agent is not via the alimentary canal. |
| PLACTRNS | http://hl7.org/fhir/v3/ActCode | transplacental transmission | Communication of an agent from a living subject to the progeny of that living subject via agent migration across the maternal-fetal placental membranes while in utero. |
| SEXTRNS | http://hl7.org/fhir/v3/ActCode | sexual transmission | Communication of an agent from one living subject to another living subject through direct contact with genital or oral tissues as part of a sexual act. |
| TRNSFTRNS | http://hl7.org/fhir/v3/ActCode | transfusion transmission | Communication of an agent from one living subject to another living subject through direct contact with blood or blood products where the contact with blood is part of a therapeutic procedure. |
| VECTRNS | http://hl7.org/fhir/v3/ActCode | vector-borne transmission | Communication of an agent from a living subject acting as a required intermediary in the agent transmission process to a recipient living subject via direct contact. |
| WATTRNS | http://hl7.org/fhir/v3/ActCode | water-borne transmission | Communication of an agent from a contaminated water source to a living subject whether the water is ingested as a food or not. The route of entry of the water may be through any bodily orifice. |
| _ObservationQualityMeasureAttribute | http://hl7.org/fhir/v3/ActCode | ObservationQualityMeasureAttribute | Codes used to define various metadata aspects of a health quality measure. |
| AGGREGATE | http://hl7.org/fhir/v3/ActCode | aggregate measure observation | Indicates that the observation is carrying out an aggregation calculation, contained in the value element. |
| CMPMSRMTH | http://hl7.org/fhir/v3/ActCode | composite measure method | Indicates what method is used in a quality measure to combine the component measure results included in an composite measure. |
| CMPMSRSCRWGHT | http://hl7.org/fhir/v3/ActCode | component measure scoring weight | An attribute of a quality measure describing the weight this component measure score is to carry in determining the overall composite measure final score. The value is real value greater than 0 and less than 1.0. Each component measure score will be multiplied by its CMPMSRSCRWGHT and then summed with the other component measures to determine the final overall composite measure score. The sum across all CMPMSRSCRWGHT values within a single composite measure SHALL be 1.0. The value assigned is scoped to the composite measure referencing this component measure only. |
| COPY | http://hl7.org/fhir/v3/ActCode | copyright | Identifies the organization(s) who own the intellectual property represented by the eMeasure. |
| CRS | http://hl7.org/fhir/v3/ActCode | clinical recommendation statement | Summary of relevant clinical guidelines or other clinical recommendations supporting this eMeasure. |
| DEF | http://hl7.org/fhir/v3/ActCode | definition | Description of individual terms, provided as needed. |
| DISC | http://hl7.org/fhir/v3/ActCode | disclaimer | Disclaimer information for the eMeasure. |
| FINALDT | http://hl7.org/fhir/v3/ActCode | finalized date/time | The timestamp when the eMeasure was last packaged in the Measure Authoring Tool. |
| GUIDE | http://hl7.org/fhir/v3/ActCode | guidance | Used to allow measure developers to provide additional guidance for implementers to understand greater specificity than could be provided in the logic for data criteria. |
| IDUR | http://hl7.org/fhir/v3/ActCode | improvement notation | Information on whether an increase or decrease in score is the preferred result (e.g., a higher score indicates better quality OR a lower score indicates better quality OR quality is within a range). |
| ITMCNT | http://hl7.org/fhir/v3/ActCode | items counted | Describes the items counted by the measure (e.g., patients, encounters, procedures, etc.) |
| KEY | http://hl7.org/fhir/v3/ActCode | keyword | A significant word that aids in discoverability. |
| MEDT | http://hl7.org/fhir/v3/ActCode | measurement end date | The end date of the measurement period. |
| MSD | http://hl7.org/fhir/v3/ActCode | measurement start date | The start date of the measurement period. |
| MSRADJ | http://hl7.org/fhir/v3/ActCode | risk adjustment | The method of adjusting for clinical severity and conditions present at the start of care that can influence patient outcomes for making valid comparisons of outcome measures across providers. Indicates whether an eMeasure is subject to the statistical process for reducing, removing, or clarifying the influences of confounding factors to allow more useful comparisons. |
| MSRAGG | http://hl7.org/fhir/v3/ActCode | rate aggregation | Describes how to combine information calculated based on logic in each of several populations into one summarized result. It can also be used to describe how to risk adjust the data based on supplemental data elements described in the eMeasure. (e.g., pneumonia hospital measures antibiotic selection in the ICU versus non-ICU and then the roll-up of the two). Open Issue: The description does NOT align well with the definition used in the HQMF specfication; correct the MSGAGG definition, and the possible distinction of MSRAGG as a child of AGGREGATE. |
| MSRIMPROV | http://hl7.org/fhir/v3/ActCode | health quality measure improvement notation | Information on whether an increase or decrease in score is the preferred result. This should reflect information on which way is better, an increase or decrease in score. |
| MSRJUR | http://hl7.org/fhir/v3/ActCode | jurisdiction | The list of jurisdiction(s) for which the measure applies. |
| MSRRPTR | http://hl7.org/fhir/v3/ActCode | reporter type | Type of person or organization that is expected to report the issue. |
| MSRRPTTIME | http://hl7.org/fhir/v3/ActCode | timeframe for reporting | The maximum time that may elapse following completion of the measure until the measure report must be sent to the receiver. |
| MSRSCORE | http://hl7.org/fhir/v3/ActCode | measure scoring | Indicates how the calculation is performed for the eMeasure (e.g., proportion, continuous variable, ratio) |
| MSRSET | http://hl7.org/fhir/v3/ActCode | health quality measure care setting | Location(s) in which care being measured is rendered Usage Note: MSRSET is used rather than RoleCode because the setting applies to what is being measured, as opposed to participating directly in the health quality measure documantion itself). |
| MSRTOPIC | http://hl7.org/fhir/v3/ActCode | health quality measure topic type | health quality measure topic type |
| MSRTP | http://hl7.org/fhir/v3/ActCode | measurement period | The time period for which the eMeasure applies. |
| MSRTYPE | http://hl7.org/fhir/v3/ActCode | measure type | Indicates whether the eMeasure is used to examine a process or an outcome over time (e.g., Structure, Process, Outcome). |
| RAT | http://hl7.org/fhir/v3/ActCode | rationale | Succinct statement of the need for the measure. Usually includes statements pertaining to Importance criterion: impact, gap in care and evidence. |
| REF | http://hl7.org/fhir/v3/ActCode | reference | Identifies bibliographic citations or references to clinical practice guidelines, sources of evidence, or other relevant materials supporting the intent and rationale of the eMeasure. |
| SDE | http://hl7.org/fhir/v3/ActCode | supplemental data elements | Comparison of results across strata can be used to show where disparities exist or where there is a need to expose differences in results. For example, Centers for Medicare & Medicaid Services (CMS) in the U.S. defines four required Supplemental Data Elements (payer, ethnicity, race, and gender), which are variables used to aggregate data into various subgroups. Additional supplemental data elements required for risk adjustment or other purposes of data aggregation can be included in the Supplemental Data Element section. |
| STRAT | http://hl7.org/fhir/v3/ActCode | stratification | Describes the strata for which the measure is to be evaluated. There are three examples of reasons for stratification based on existing work. These include: (1) evaluate the measure based on different age groupings within the population described in the measure (e.g., evaluate the whole [age 14-25] and each sub-stratum [14-19] and [20-25]); (2) evaluate the eMeasure based on either a specific condition, a specific discharge location, or both; (3) evaluate the eMeasure based on different locations within a facility (e.g., evaluate the overall rate for all intensive care units and also some strata include additional findings [specific birth weights for neonatal intensive care units]). |
| TRANF | http://hl7.org/fhir/v3/ActCode | transmission format | Can be a URL or hyperlinks that link to the transmission formats that are specified for a particular reporting program. |
| USE | http://hl7.org/fhir/v3/ActCode | notice of use | Usage notes. |
| _ObservationSequenceType | http://hl7.org/fhir/v3/ActCode | ObservationSequenceType | ObservationSequenceType |
| TIME_ABSOLUTE | http://hl7.org/fhir/v3/ActCode | absolute time sequence | A sequence of values in the "absolute" time domain. This is the same time domain that all HL7 timestamps use. It is time as measured by the Gregorian calendar |
| TIME_RELATIVE | http://hl7.org/fhir/v3/ActCode | relative time sequence | A sequence of values in a "relative" time domain. The time is measured relative to the earliest effective time in the Observation Series containing this sequence. |
| _ObservationSeriesType | http://hl7.org/fhir/v3/ActCode | ObservationSeriesType | ObservationSeriesType |
| _ECGObservationSeriesType | http://hl7.org/fhir/v3/ActCode | ECGObservationSeriesType | ECGObservationSeriesType |
| REPRESENTATIVE_BEAT | http://hl7.org/fhir/v3/ActCode | ECG representative beat waveforms | This Observation Series type contains waveforms of a "representative beat" (a.k.a. "median beat" or "average beat"). The waveform samples are measured in relative time, relative to the beginning of the beat as defined by the Observation Series effective time. The waveforms are not directly acquired from the subject, but rather algorithmically derived from the "rhythm" waveforms. |
| RHYTHM | http://hl7.org/fhir/v3/ActCode | ECG rhythm waveforms | This Observation type contains ECG "rhythm" waveforms. The waveform samples are measured in absolute time (a.k.a. "subject time" or "effective time"). These waveforms are usually "raw" with some minimal amount of noise reduction and baseline filtering applied. |
| _PatientImmunizationRelatedObservationType | http://hl7.org/fhir/v3/ActCode | PatientImmunizationRelatedObservationType | Description: Reporting codes that are related to an immunization event. |
| CLSSRM | http://hl7.org/fhir/v3/ActCode | classroom | Description: The class room associated with the patient during the immunization event. |
| GRADE | http://hl7.org/fhir/v3/ActCode | grade | Description: The school grade or level the patient was in when immunized. |
| SCHL | http://hl7.org/fhir/v3/ActCode | school | Description: The school the patient attended when immunized. |
| SCHLDIV | http://hl7.org/fhir/v3/ActCode | school division | Description: The school division or district associated with the patient during the immunization event. |
| TEACHER | http://hl7.org/fhir/v3/ActCode | teacher | Description: The patient's teacher when immunized. |
| _PopulationInclusionObservationType | http://hl7.org/fhir/v3/ActCode | PopulationInclusionObservationType | Observation types for specifying criteria used to assert that a subject is included in a particular population. |
| DENEX | http://hl7.org/fhir/v3/ActCode | denominator exclusions | Criteria which specify subjects who should be removed from the eMeasure population and denominator before determining if numerator criteria are met. Denominator exclusions are used in proportion and ratio measures to help narrow the denominator. |
| DENEXCEP | http://hl7.org/fhir/v3/ActCode | denominator exceptions | Criteria which specify the removal of a subject, procedure or unit of measurement from the denominator, only if the numerator criteria are not met. Denominator exceptions allow for adjustment of the calculated score for those providers with higher risk populations. Denominator exceptions are used only in proportion eMeasures. They are not appropriate for ratio or continuous variable eMeasures. Denominator exceptions allow for the exercise of clinical judgment and should be specifically defined where capturing the information in a structured manner fits the clinical workflow. Generic denominator exception reasons used in proportion eMeasures fall into three general categories: Medical reasons Patient (or subject) reasons System reasons |
| DENOM | http://hl7.org/fhir/v3/ActCode | denominator | Criteria for specifying the entities to be evaluated by a specific quality measure, based on a shared common set of characteristics (within a specific measurement set to which a given measure belongs). The denominator can be the same as the initial population, or it may be a subset of the initial population to further constrain it for the purpose of the eMeasure. Different measures within an eMeasure set may have different denominators. Continuous Variable eMeasures do not have a denominator, but instead define a measure population. |
| IPOP | http://hl7.org/fhir/v3/ActCode | initial population | Criteria for specifying the entities to be evaluated by a specific quality measure, based on a shared common set of characteristics (within a specific measurement set to which a given measure belongs). |
| IPPOP | http://hl7.org/fhir/v3/ActCode | initial patient population | Criteria for specifying the patients to be evaluated by a specific quality measure, based on a shared common set of characteristics (within a specific measurement set to which a given measure belongs). Details often include information based upon specific age groups, diagnoses, diagnostic and procedure codes, and enrollment periods. |
| MSRPOPL | http://hl7.org/fhir/v3/ActCode | measure population | Criteria for specifying the measure population as a narrative description (e.g., all patients seen in the Emergency Department during the measurement period). This is used only in continuous variable eMeasures. |
| MSRPOPLEX | http://hl7.org/fhir/v3/ActCode | measure population exclusions | Criteria for specifying subjects who should be removed from the eMeasure's Initial Population and Measure Population. Measure Population Exclusions are used in Continuous Variable measures to help narrow the Measure Population before determining the value(s) of the continuous variable(s). |
| NUMER | http://hl7.org/fhir/v3/ActCode | numerator | Criteria for specifying the processes or outcomes expected for each patient, procedure, or other unit of measurement defined in the denominator for proportion measures, or related to (but not directly derived from) the denominator for ratio measures (e.g., a numerator listing the number of central line blood stream infections and a denominator indicating the days per thousand of central line usage in a specific time period). |
| NUMEX | http://hl7.org/fhir/v3/ActCode | numerator exclusions | Criteria for specifying instances that should not be included in the numerator data. (e.g., if the number of central line blood stream infections per 1000 catheter days were to exclude infections with a specific bacterium, that bacterium would be listed as a numerator exclusion). Numerator Exclusions are used only in ratio eMeasures. |
| _PreferenceObservationType | http://hl7.org/fhir/v3/ActCode | _PreferenceObservationType | Types of observations that can be made about Preferences. |
| PREFSTRENGTH | http://hl7.org/fhir/v3/ActCode | preference strength | An observation about how important a preference is to the target of the preference. |
| ADVERSE_REACTION | http://hl7.org/fhir/v3/ActCode | Adverse Reaction | Indicates that the observation is of an unexpected negative occurrence in the subject suspected to result from the subject's exposure to one or more agents. Observation values would be the symptom resulting from the reaction. |
| ASSERTION | http://hl7.org/fhir/v3/ActCode | Assertion | Description:Refines classCode OBS to indicate an observation in which observation.value contains a finding or other nominalized statement, where the encoded information in Observation.value is not altered by Observation.code. For instance, observation.code="ASSERTION" and observation.value="fracture of femur present" is an assertion of a clinical finding of femur fracture. |
| CASESER | http://hl7.org/fhir/v3/ActCode | case seriousness criteria | Definition:An observation that provides a characterization of the level of harm to an investigation subject as a result of a reaction or event. |
| CDIO | http://hl7.org/fhir/v3/ActCode | case disease imported observation | An observation that states whether the disease was likely acquired outside the jurisdiction of observation, and if so, the nature of the inter-jurisdictional relationship. OpenIssue: This code could be moved to LOINC if it can be done before there are significant implemenations using it. |
| CRIT | http://hl7.org/fhir/v3/ActCode | criticality | A clinical judgment as to the worst case result of a future exposure (including substance administration). When the worst case result is assessed to have a life-threatening or organ system threatening potential, it is considered to be of high criticality. |
| CTMO | http://hl7.org/fhir/v3/ActCode | case transmission mode observation | An observation that states the mechanism by which disease was acquired by the living subject involved in the public health case. OpenIssue: This code could be moved to LOINC if it can be done before there are significant implemenations using it. |
| DX | http://hl7.org/fhir/v3/ActCode | ObservationDiagnosisTypes | Includes all codes defining types of indications such as diagnosis, symptom and other indications such as contrast agents for lab tests. |
| ADMDX | http://hl7.org/fhir/v3/ActCode | admitting diagnosis | Admitting diagnosis are the diagnoses documented for administrative purposes as the basis for a hospital admission. |
| DISDX | http://hl7.org/fhir/v3/ActCode | discharge diagnosis | Discharge diagnosis are the diagnoses documented for administrative purposes as the time of hospital discharge. |
| INTDX | http://hl7.org/fhir/v3/ActCode | intermediate diagnosis | Intermediate diagnoses are those diagnoses documented for administrative purposes during the course of a hospital stay. |
| NOI | http://hl7.org/fhir/v3/ActCode | nature of injury | The type of injury that the injury coding specifies. |
| GISTIER | http://hl7.org/fhir/v3/ActCode | GIS tier | Description: Accuracy determined as per the GIS tier code system. |
| HHOBS | http://hl7.org/fhir/v3/ActCode | household situation observation | Indicates that the observation is of a person’s living situation in a household including the household composition and circumstances. |
| ISSUE | http://hl7.org/fhir/v3/ActCode | detected issue | There is a clinical issue for the therapy that makes continuation of the therapy inappropriate. Open Issue: The definition of this code does not correctly represent the concept space of its specializations (children) |
| _ActAdministrativeDetectedIssueCode | http://hl7.org/fhir/v3/ActCode | ActAdministrativeDetectedIssueCode | Identifies types of detectyed issues for Act class "ALRT" for the administrative and patient administrative acts domains. |
| _ActAdministrativeAuthorizationDetectedIssueCode | http://hl7.org/fhir/v3/ActCode | ActAdministrativeAuthorizationDetectedIssueCode | ActAdministrativeAuthorizationDetectedIssueCode |
| NAT | http://hl7.org/fhir/v3/ActCode | Insufficient authorization | The requesting party has insufficient authorization to invoke the interaction. |
| SUPPRESSED | http://hl7.org/fhir/v3/ActCode | record suppressed | Description: One or more records in the query response have been suppressed due to consent or privacy restrictions. |
| VALIDAT | http://hl7.org/fhir/v3/ActCode | validation issue | Description:The specified element did not pass business-rule validation. |
| KEY204 | http://hl7.org/fhir/v3/ActCode | Unknown key identifier | The ID of the patient, order, etc., was not found. Used for transactions other than additions, e.g. transfer of a non-existent patient. |
| KEY205 | http://hl7.org/fhir/v3/ActCode | Duplicate key identifier | The ID of the patient, order, etc., already exists. Used in response to addition transactions (Admit, New Order, etc.). |
| COMPLY | http://hl7.org/fhir/v3/ActCode | Compliance Alert | There may be an issue with the patient complying with the intentions of the proposed therapy |
| DUPTHPY | http://hl7.org/fhir/v3/ActCode | Duplicate Therapy Alert | The proposed therapy appears to duplicate an existing therapy |
| DUPTHPCLS | http://hl7.org/fhir/v3/ActCode | duplicate therapeutic alass alert | Description:The proposed therapy appears to have the same intended therapeutic benefit as an existing therapy, though the specific mechanisms of action vary. |
| DUPTHPGEN | http://hl7.org/fhir/v3/ActCode | duplicate generic alert | Description:The proposed therapy appears to have the same intended therapeutic benefit as an existing therapy and uses the same mechanisms of action as the existing therapy. |
| ABUSE | http://hl7.org/fhir/v3/ActCode | commonly abused/misused alert | Description:The proposed therapy is frequently misused or abused and therefore should be used with caution and/or monitoring. |
| FRAUD | http://hl7.org/fhir/v3/ActCode | potential fraud | Description:The request is suspected to have a fraudulent basis. |
| PLYDOC | http://hl7.org/fhir/v3/ActCode | Poly-orderer Alert | A similar or identical therapy was recently ordered by a different practitioner. |
| PLYPHRM | http://hl7.org/fhir/v3/ActCode | Poly-supplier Alert | This patient was recently supplied a similar or identical therapy from a different pharmacy or supplier. |
| DOSE | http://hl7.org/fhir/v3/ActCode | Dosage problem | Proposed dosage instructions for therapy differ from standard practice. |
| DOSECOND | http://hl7.org/fhir/v3/ActCode | dosage-condition alert | Description:Proposed dosage is inappropriate due to patient's medical condition. |
| DOSEDUR | http://hl7.org/fhir/v3/ActCode | Dose-Duration Alert | Proposed length of therapy differs from standard practice. |
| DOSEDURH | http://hl7.org/fhir/v3/ActCode | Dose-Duration High Alert | Proposed length of therapy is longer than standard practice |
| DOSEDURHIND | http://hl7.org/fhir/v3/ActCode | Dose-Duration High for Indication Alert | Proposed length of therapy is longer than standard practice for the identified indication or diagnosis |
| DOSEDURL | http://hl7.org/fhir/v3/ActCode | Dose-Duration Low Alert | Proposed length of therapy is shorter than that necessary for therapeutic effect |
| DOSEDURLIND | http://hl7.org/fhir/v3/ActCode | Dose-Duration Low for Indication Alert | Proposed length of therapy is shorter than standard practice for the identified indication or diagnosis |
| DOSEH | http://hl7.org/fhir/v3/ActCode | High Dose Alert | Proposed dosage exceeds standard practice |
| DOSEHINDA | http://hl7.org/fhir/v3/ActCode | High Dose for Age Alert | Proposed dosage exceeds standard practice for the patient's age |
| DOSEHIND | http://hl7.org/fhir/v3/ActCode | High Dose for Indication Alert | High Dose for Indication Alert |
| DOSEHINDSA | http://hl7.org/fhir/v3/ActCode | High Dose for Height/Surface Area Alert | Proposed dosage exceeds standard practice for the patient's height or body surface area |
| DOSEHINDW | http://hl7.org/fhir/v3/ActCode | High Dose for Weight Alert | Proposed dosage exceeds standard practice for the patient's weight |
| DOSEIVL | http://hl7.org/fhir/v3/ActCode | Dose-Interval Alert | Proposed dosage interval/timing differs from standard practice |
| DOSEIVLIND | http://hl7.org/fhir/v3/ActCode | Dose-Interval for Indication Alert | Proposed dosage interval/timing differs from standard practice for the identified indication or diagnosis |
| DOSEL | http://hl7.org/fhir/v3/ActCode | Low Dose Alert | Proposed dosage is below suggested therapeutic levels |
| DOSELINDA | http://hl7.org/fhir/v3/ActCode | Low Dose for Age Alert | Proposed dosage is below suggested therapeutic levels for the patient's age |
| DOSELIND | http://hl7.org/fhir/v3/ActCode | Low Dose for Indication Alert | Low Dose for Indication Alert |
| DOSELINDSA | http://hl7.org/fhir/v3/ActCode | Low Dose for Height/Surface Area Alert | Proposed dosage is below suggested therapeutic levels for the patient's height or body surface area |
| DOSELINDW | http://hl7.org/fhir/v3/ActCode | Low Dose for Weight Alert | Proposed dosage is below suggested therapeutic levels for the patient's weight |
| MDOSE | http://hl7.org/fhir/v3/ActCode | maximum dosage reached | Description:The maximum quantity of this drug allowed to be administered within a particular time-range (month, year, lifetime) has been reached or exceeded. |
| OBSA | http://hl7.org/fhir/v3/ActCode | Observation Alert | Proposed therapy may be inappropriate or contraindicated due to conditions or characteristics of the patient |
| AGE | http://hl7.org/fhir/v3/ActCode | Age Alert | Proposed therapy may be inappropriate or contraindicated due to patient age |
| ADALRT | http://hl7.org/fhir/v3/ActCode | adult alert | Proposed therapy is outside of the standard practice for an adult patient. |
| GEALRT | http://hl7.org/fhir/v3/ActCode | geriatric alert | Proposed therapy is outside of standard practice for a geriatric patient. |
| PEALRT | http://hl7.org/fhir/v3/ActCode | pediatric alert | Proposed therapy is outside of the standard practice for a pediatric patient. |
| COND | http://hl7.org/fhir/v3/ActCode | Condition Alert | Proposed therapy may be inappropriate or contraindicated due to an existing/recent patient condition or diagnosis |
| HGHT | http://hl7.org/fhir/v3/ActCode | HGHT | |
| LACT | http://hl7.org/fhir/v3/ActCode | Lactation Alert | Proposed therapy may be inappropriate or contraindicated when breast-feeding |
| PREG | http://hl7.org/fhir/v3/ActCode | Pregnancy Alert | Proposed therapy may be inappropriate or contraindicated during pregnancy |
| WGHT | http://hl7.org/fhir/v3/ActCode | WGHT | |
| CREACT | http://hl7.org/fhir/v3/ActCode | common reaction alert | Description:Proposed therapy may be inappropriate or contraindicated because of a common but non-patient specific reaction to the product. Example:There is no record of a specific sensitivity for the patient, but the presence of the sensitivity is common and therefore caution is warranted. |
| GEN | http://hl7.org/fhir/v3/ActCode | Genetic Alert | Proposed therapy may be inappropriate or contraindicated due to patient genetic indicators. |
| GEND | http://hl7.org/fhir/v3/ActCode | Gender Alert | Proposed therapy may be inappropriate or contraindicated due to patient gender. |
| LAB | http://hl7.org/fhir/v3/ActCode | Lab Alert | Proposed therapy may be inappropriate or contraindicated due to recent lab test results |
| REACT | http://hl7.org/fhir/v3/ActCode | Reaction Alert | Proposed therapy may be inappropriate or contraindicated based on the potential for a patient reaction to the proposed product |
| ALGY | http://hl7.org/fhir/v3/ActCode | Allergy Alert | Proposed therapy may be inappropriate or contraindicated because of a recorded patient allergy to the proposed product. (Allergies are immune based reactions.) |
| INT | http://hl7.org/fhir/v3/ActCode | Intolerance Alert | Proposed therapy may be inappropriate or contraindicated because of a recorded patient intolerance to the proposed product. (Intolerances are non-immune based sensitivities.) |
| RREACT | http://hl7.org/fhir/v3/ActCode | Related Reaction Alert | Proposed therapy may be inappropriate or contraindicated because of a potential patient reaction to a cross-sensitivity related product. |
| RALG | http://hl7.org/fhir/v3/ActCode | Related Allergy Alert | Proposed therapy may be inappropriate or contraindicated because of a recorded patient allergy to a cross-sensitivity related product. (Allergies are immune based reactions.) |
| RAR | http://hl7.org/fhir/v3/ActCode | Related Prior Reaction Alert | Proposed therapy may be inappropriate or contraindicated because of a recorded prior adverse reaction to a cross-sensitivity related product. |
| RINT | http://hl7.org/fhir/v3/ActCode | Related Intolerance Alert | Proposed therapy may be inappropriate or contraindicated because of a recorded patient intolerance to a cross-sensitivity related product. (Intolerances are non-immune based sensitivities.) |
| BUS | http://hl7.org/fhir/v3/ActCode | business constraint violation | Description:A local business rule relating multiple elements has been violated. |
| CODE_INVAL | http://hl7.org/fhir/v3/ActCode | code is not valid | Description:The specified code is not valid against the list of codes allowed for the element. |
| CODE_DEPREC | http://hl7.org/fhir/v3/ActCode | code has been deprecated | Description:The specified code has been deprecated and should no longer be used. Select another code from the code system. |
| FORMAT | http://hl7.org/fhir/v3/ActCode | invalid format | Description:The element does not follow the formatting or type rules defined for the field. |
| ILLEGAL | http://hl7.org/fhir/v3/ActCode | illegal | Description:The request is missing elements or contains elements which cause it to not meet the legal standards for actioning. |
| LEN_RANGE | http://hl7.org/fhir/v3/ActCode | length out of range | Description:The length of the data specified falls out of the range defined for the element. |
| LEN_LONG | http://hl7.org/fhir/v3/ActCode | length is too long | Description:The length of the data specified is greater than the maximum length defined for the element. |
| LEN_SHORT | http://hl7.org/fhir/v3/ActCode | length is too short | Description:The length of the data specified is less than the minimum length defined for the element. |
| MISSCOND | http://hl7.org/fhir/v3/ActCode | conditional element missing | Description:The specified element must be specified with a non-null value under certain conditions. In this case, the conditions are true but the element is still missing or null. |
| MISSMAND | http://hl7.org/fhir/v3/ActCode | mandatory element missing | Description:The specified element is mandatory and was not included in the instance. |
| NODUPS | http://hl7.org/fhir/v3/ActCode | duplicate values are not permitted | Description:More than one element with the same value exists in the set. Duplicates not permission in this set in a set. |
| NOPERSIST | http://hl7.org/fhir/v3/ActCode | element will not be persisted | Description: Element in submitted message will not persist in data storage based on detected issue. |
| REP_RANGE | http://hl7.org/fhir/v3/ActCode | repetitions out of range | Description:The number of repeating elements falls outside the range of the allowed number of repetitions. |
| MAXOCCURS | http://hl7.org/fhir/v3/ActCode | repetitions above maximum | Description:The number of repeating elements is above the maximum number of repetitions allowed. |
| MINOCCURS | http://hl7.org/fhir/v3/ActCode | repetitions below minimum | Description:The number of repeating elements is below the minimum number of repetitions allowed. |
| _ActAdministrativeRuleDetectedIssueCode | http://hl7.org/fhir/v3/ActCode | ActAdministrativeRuleDetectedIssueCode | ActAdministrativeRuleDetectedIssueCode |
| KEY206 | http://hl7.org/fhir/v3/ActCode | non-matching identification | Description: Metadata associated with the identification (e.g. name or gender) does not match the identification being verified. |
| OBSOLETE | http://hl7.org/fhir/v3/ActCode | obsolete record returned | Description: One or more records in the query response have a status of 'obsolete'. |
| _ActSuppliedItemDetectedIssueCode | http://hl7.org/fhir/v3/ActCode | ActSuppliedItemDetectedIssueCode | Identifies types of detected issues regarding the administration or supply of an item to a patient. |
| _AdministrationDetectedIssueCode | http://hl7.org/fhir/v3/ActCode | AdministrationDetectedIssueCode | Administration of the proposed therapy may be inappropriate or contraindicated as proposed |
| _AppropriatenessDetectedIssueCode | http://hl7.org/fhir/v3/ActCode | AppropriatenessDetectedIssueCode | AppropriatenessDetectedIssueCode |
| _InteractionDetectedIssueCode | http://hl7.org/fhir/v3/ActCode | InteractionDetectedIssueCode | InteractionDetectedIssueCode |
| FOOD | http://hl7.org/fhir/v3/ActCode | Food Interaction Alert | Proposed therapy may interact with certain foods |
| TPROD | http://hl7.org/fhir/v3/ActCode | Therapeutic Product Alert | Proposed therapy may interact with an existing or recent therapeutic product |
| DRG | http://hl7.org/fhir/v3/ActCode | Drug Interaction Alert | Proposed therapy may interact with an existing or recent drug therapy |
| NHP | http://hl7.org/fhir/v3/ActCode | Natural Health Product Alert | Proposed therapy may interact with existing or recent natural health product therapy |
| NONRX | http://hl7.org/fhir/v3/ActCode | Non-Prescription Interaction Alert | Proposed therapy may interact with a non-prescription drug (e.g. alcohol, tobacco, Aspirin) |
| PREVINEF | http://hl7.org/fhir/v3/ActCode | previously ineffective | Definition:The same or similar treatment has previously been attempted with the patient without achieving a positive effect. |
| DACT | http://hl7.org/fhir/v3/ActCode | drug action detected issue | Description:Proposed therapy may be contraindicated or ineffective based on an existing or recent drug therapy. |
| TIME | http://hl7.org/fhir/v3/ActCode | timing detected issue | Description:Proposed therapy may be inappropriate or ineffective based on the proposed start or end time. |
| ALRTENDLATE | http://hl7.org/fhir/v3/ActCode | end too late alert | Definition:Proposed therapy may be inappropriate or ineffective because the end of administration is too close to another planned therapy. |
| ALRTSTRTLATE | http://hl7.org/fhir/v3/ActCode | start too late alert | Definition:Proposed therapy may be inappropriate or ineffective because the start of administration is too late after the onset of the condition. |
| _TimingDetectedIssueCode | http://hl7.org/fhir/v3/ActCode | TimingDetectedIssueCode | Proposed therapy may be inappropriate or ineffective based on the proposed start or end time. |
| ENDLATE | http://hl7.org/fhir/v3/ActCode | End Too Late Alert | Proposed therapy may be inappropriate or ineffective because the end of administration is too close to another planned therapy |
| STRTLATE | http://hl7.org/fhir/v3/ActCode | Start Too Late Alert | Proposed therapy may be inappropriate or ineffective because the start of administration is too late after the onset of the condition |
| _SupplyDetectedIssueCode | http://hl7.org/fhir/v3/ActCode | SupplyDetectedIssueCode | Supplying the product at this time may be inappropriate or indicate compliance issues with the associated therapy |
| ALLDONE | http://hl7.org/fhir/v3/ActCode | already performed | Definition:The requested action has already been performed and so this request has no effect |
| FULFIL | http://hl7.org/fhir/v3/ActCode | fulfillment alert | Definition:The therapy being performed is in some way out of alignment with the requested therapy. |
| NOTACTN | http://hl7.org/fhir/v3/ActCode | no longer actionable | Definition:The status of the request being fulfilled has changed such that it is no longer actionable. This may be because the request has expired, has already been completely fulfilled or has been otherwise stopped or disabled. (Not used for 'suspended' orders.) |
| NOTEQUIV | http://hl7.org/fhir/v3/ActCode | not equivalent alert | Definition:The therapy being performed is not sufficiently equivalent to the therapy which was requested. |
| NOTEQUIVGEN | http://hl7.org/fhir/v3/ActCode | not generically equivalent alert | Definition:The therapy being performed is not generically equivalent (having the identical biological action) to the therapy which was requested. |
| NOTEQUIVTHER | http://hl7.org/fhir/v3/ActCode | not therapeutically equivalent alert | Definition:The therapy being performed is not therapeutically equivalent (having the same overall patient effect) to the therapy which was requested. |
| TIMING | http://hl7.org/fhir/v3/ActCode | event timing incorrect alert | Definition:The therapy is being performed at a time which diverges from the time the therapy was requested |
| INTERVAL | http://hl7.org/fhir/v3/ActCode | outside requested time | Definition:The therapy action is being performed outside the bounds of the time period requested |
| MINFREQ | http://hl7.org/fhir/v3/ActCode | too soon within frequency based on the usage | Definition:The therapy action is being performed too soon after the previous occurrence based on the requested frequency |
| HELD | http://hl7.org/fhir/v3/ActCode | held/suspended alert | Definition:There should be no actions taken in fulfillment of a request that has been held or suspended. |
| TOOLATE | http://hl7.org/fhir/v3/ActCode | Refill Too Late Alert | The patient is receiving a subsequent fill significantly later than would be expected based on the amount previously supplied and the therapy dosage instructions |
| TOOSOON | http://hl7.org/fhir/v3/ActCode | Refill Too Soon Alert | The patient is receiving a subsequent fill significantly earlier than would be expected based on the amount previously supplied and the therapy dosage instructions |
| HISTORIC | http://hl7.org/fhir/v3/ActCode | record recorded as historical | Description: While the record was accepted in the repository, there is a more recent version of a record of this type. |
| PATPREF | http://hl7.org/fhir/v3/ActCode | violates stated preferences | Definition:The proposed therapy goes against preferences or consent constraints recorded in the patient's record. |
| PATPREFALT | http://hl7.org/fhir/v3/ActCode | violates stated preferences, alternate available | Definition:The proposed therapy goes against preferences or consent constraints recorded in the patient's record. An alternate therapy meeting those constraints is available. |
| KSUBJ | http://hl7.org/fhir/v3/ActCode | knowledge subject | Categorization of types of observation that capture the main clinical knowledge subject which may be a medication, a laboratory test, a disease. |
| KSUBT | http://hl7.org/fhir/v3/ActCode | knowledge subtopic | Categorization of types of observation that capture a knowledge subtopic which might be treatment, etiology, or prognosis. |
| OINT | http://hl7.org/fhir/v3/ActCode | intolerance | Hypersensitivity resulting in an adverse reaction upon exposure to an agent. |
| ALG | http://hl7.org/fhir/v3/ActCode | Allergy | Hypersensitivity to an agent caused by an immunologic response to an initial exposure |
| DALG | http://hl7.org/fhir/v3/ActCode | Drug Allergy | An allergy to a pharmaceutical product. |
| EALG | http://hl7.org/fhir/v3/ActCode | Environmental Allergy | An allergy to a substance other than a drug or a food. E.g. Latex, pollen, etc. |
| FALG | http://hl7.org/fhir/v3/ActCode | Food Allergy | An allergy to a substance generally consumed for nutritional purposes. |
| DINT | http://hl7.org/fhir/v3/ActCode | Drug Intolerance | Hypersensitivity resulting in an adverse reaction upon exposure to a drug. |
| DNAINT | http://hl7.org/fhir/v3/ActCode | Drug Non-Allergy Intolerance | Hypersensitivity to an agent caused by a mechanism other than an immunologic response to an initial exposure |
| EINT | http://hl7.org/fhir/v3/ActCode | Environmental Intolerance | Hypersensitivity resulting in an adverse reaction upon exposure to environmental conditions. |
| ENAINT | http://hl7.org/fhir/v3/ActCode | Environmental Non-Allergy Intolerance | Hypersensitivity to an agent caused by a mechanism other than an immunologic response to an initial exposure |
| FINT | http://hl7.org/fhir/v3/ActCode | Food Intolerance | Hypersensitivity resulting in an adverse reaction upon exposure to food. |
| FNAINT | http://hl7.org/fhir/v3/ActCode | Food Non-Allergy Intolerance | Hypersensitivity to an agent caused by a mechanism other than an immunologic response to an initial exposure |
| NAINT | http://hl7.org/fhir/v3/ActCode | Non-Allergy Intolerance | Hypersensitivity to an agent caused by a mechanism other than an immunologic response to an initial exposure |
| SEV | http://hl7.org/fhir/v3/ActCode | Severity Observation | A subjective evaluation of the seriousness or intensity associated with another observation. |
| _FDALabelData | http://hl7.org/fhir/v3/ActCode | FDALabelData | FDA label data |
| FDACOATING | http://hl7.org/fhir/v3/ActCode | coating | FDA label coating |
| FDACOLOR | http://hl7.org/fhir/v3/ActCode | color | FDA label color |
| FDAIMPRINTCD | http://hl7.org/fhir/v3/ActCode | imprint code | FDA label imprint code |
| FDALOGO | http://hl7.org/fhir/v3/ActCode | logo | FDA label logo |
| FDASCORING | http://hl7.org/fhir/v3/ActCode | scoring | FDA label scoring |
| FDASHAPE | http://hl7.org/fhir/v3/ActCode | shape | FDA label shape |
| FDASIZE | http://hl7.org/fhir/v3/ActCode | size | FDA label size |
| 1-8 | http://loinc.org | Acyclovir [Susceptibility] | |
| 10-9 | http://loinc.org | Amdinocillin [Susceptibility] by Serum bactericidal titer | |
| 100-8 | http://loinc.org | Cefoperazone [Susceptibility] by Minimum inhibitory concentration (MIC) | |
| 1000-9 | http://loinc.org | DBG Ab [Presence] in Serum or Plasma from Blood product unit | |
| 10000-8 | http://loinc.org | R wave duration in lead AVR | |
| 10001-6 | http://loinc.org | R wave duration in lead I | |
| 10002-4 | http://loinc.org | R wave duration in lead II | |
| 10003-2 | http://loinc.org | R wave duration in lead III | |
| 10004-0 | http://loinc.org | R wave duration in lead V1 | |
| 10005-7 | http://loinc.org | R wave duration in lead V2 | |
| 10006-5 | http://loinc.org | R wave duration in lead V3 | |
| 10007-3 | http://loinc.org | R wave duration in lead V4 | |
| 10008-1 | http://loinc.org | R wave duration in lead V5 | |
| 10009-9 | http://loinc.org | R wave duration in lead V6 | |
| 1001-7 | http://loinc.org | DBG Ab [Presence] in Serum or Plasma from donor | |
| 10010-7 | http://loinc.org | R' wave amplitude in lead AVF | |
| 10011-5 | http://loinc.org | R' wave amplitude in lead AVL | |
| 10012-3 | http://loinc.org | R' wave amplitude in lead AVR | |
| 10013-1 | http://loinc.org | R' wave amplitude in lead I | |
| 10014-9 | http://loinc.org | R' wave amplitude in lead II | |
| 10015-6 | http://loinc.org | R' wave amplitude in lead III | |
| 10016-4 | http://loinc.org | R' wave amplitude in lead V1 | |
| 10017-2 | http://loinc.org | R' wave amplitude in lead V2 | |
| 10018-0 | http://loinc.org | R' wave amplitude in lead V3 | |
| 10019-8 | http://loinc.org | R' wave amplitude in lead V4 | |
| 1002-5 | http://loinc.org | DBG Ab [Presence] in Serum or Plasma | |
| 10020-6 | http://loinc.org | R' wave amplitude in lead V5 | |
| 10021-4 | http://loinc.org | R' wave amplitude in lead V6 | |
| 10022-2 | http://loinc.org | R' wave duration in lead AVF | |
| 10023-0 | http://loinc.org | R' wave duration in lead AVL | |
| 10024-8 | http://loinc.org | R' wave duration in lead AVR | |
| 10025-5 | http://loinc.org | R' wave duration in lead I | |
| 10026-3 | http://loinc.org | R' wave duration in lead II | |
| 10027-1 | http://loinc.org | R' wave duration in lead III | |
| 10028-9 | http://loinc.org | R' wave duration in lead V1 | |
| 10029-7 | http://loinc.org | R' wave duration in lead V2 | |
| 1003-3 | http://loinc.org | Indirect antiglobulin test.complement specific reagent [Presence] in Serum or Plasma | |
| 10030-5 | http://loinc.org | R' wave duration in lead V3 | |
| 10031-3 | http://loinc.org | R' wave duration in lead V4 | |
| 10032-1 | http://loinc.org | R' wave duration in lead V5 | |
| 10033-9 | http://loinc.org | R' wave duration in lead V6 | |
| 10034-7 | http://loinc.org | S wave amplitude in lead AVF | |
| 10035-4 | http://loinc.org | S wave amplitude in lead AVL | |
| 10036-2 | http://loinc.org | S wave amplitude in lead AVR | |
| 10037-0 | http://loinc.org | S wave amplitude in lead I | |
| 10038-8 | http://loinc.org | S wave amplitude in lead II | |
| 10039-6 | http://loinc.org | S wave amplitude in lead III | |
| 1004-1 | http://loinc.org | Direct antiglobulin test.complement specific reagent [Presence] on Red Blood Cells | |
| 10040-4 | http://loinc.org | S wave amplitude in lead V1 | |
| 10041-2 | http://loinc.org | S wave amplitude in lead V2 | |
| 10042-0 | http://loinc.org | S wave amplitude in lead V3 | |
| 10043-8 | http://loinc.org | S wave amplitude in lead V4 | |
| 10044-6 | http://loinc.org | S wave amplitude in lead V5 | |
| 10045-3 | http://loinc.org | S wave amplitude in lead V6 | |
| 10046-1 | http://loinc.org | S wave duration in lead AVF | |
| 10047-9 | http://loinc.org | S wave duration in lead AVL | |
| 10048-7 | http://loinc.org | S wave duration in lead AVR | |
| 10049-5 | http://loinc.org | S wave duration in lead I | |
| 1005-8 | http://loinc.org | Indirect antiglobulin test.IgG specific reagent [Presence] in Serum or Plasma | |
| 10050-3 | http://loinc.org | S wave duration in lead II | |
| 10051-1 | http://loinc.org | S wave duration in lead III | |
| 10052-9 | http://loinc.org | S wave duration in lead V1 | |
| 10053-7 | http://loinc.org | S wave duration in lead V2 | |
| 10054-5 | http://loinc.org | S wave duration in lead V3 | |
| 10055-2 | http://loinc.org | S wave duration in lead V4 | |
| 10056-0 | http://loinc.org | S wave duration in lead V5 | |
| 10057-8 | http://loinc.org | S wave duration in lead V6 | |
| 10058-6 | http://loinc.org | S' wave amplitude in lead AVF | |
| 10059-4 | http://loinc.org | S' wave amplitude in lead AVL | |
| 1006-6 | http://loinc.org | Direct antiglobulin test.IgG specific reagent [Interpretation] on Red Blood Cells | |
| 10060-2 | http://loinc.org | S' wave amplitude in lead AVR | |
| 10061-0 | http://loinc.org | S' wave amplitude in lead I | |
| 10062-8 | http://loinc.org | S' wave amplitude in lead II | |
| 10063-6 | http://loinc.org | S' wave amplitude in lead III | |
| 10064-4 | http://loinc.org | S' wave amplitude in lead V1 | |
| 10065-1 | http://loinc.org | S' wave amplitude in lead V2 | |
| 10066-9 | http://loinc.org | S' wave amplitude in lead V3 | |
| 10067-7 | http://loinc.org | S' wave amplitude in lead V4 | |
| 10068-5 | http://loinc.org | S' wave amplitude in lead V5 | |
| 10069-3 | http://loinc.org | S' wave amplitude in lead V6 | |
| 1007-4 | http://loinc.org | Direct antiglobulin test.poly specific reagent [Presence] on Red Blood Cells | |
| 10070-1 | http://loinc.org | S' wave duration in lead AVF | |
| 10071-9 | http://loinc.org | S' wave duration in lead AVL | |
| 10072-7 | http://loinc.org | S' wave duration in lead AVR | |
| 10073-5 | http://loinc.org | S' wave duration in lead I | |
| 10074-3 | http://loinc.org | S' wave duration in lead II | |
| 10075-0 | http://loinc.org | S' wave duration in lead III | |
| 10076-8 | http://loinc.org | S' wave duration in lead V1 | |
| 10077-6 | http://loinc.org | S' wave duration in lead V2 | |
| 10078-4 | http://loinc.org | S' wave duration in lead V3 | |
| 10079-2 | http://loinc.org | S' wave duration in lead V4 | |
| 1008-2 | http://loinc.org | Indirect antiglobulin test.poly specific reagent [Presence] in Serum or Plasma | |
| 10080-0 | http://loinc.org | S' wave duration in lead V5 | |
| 10081-8 | http://loinc.org | S' wave duration in lead V6 | |
| 10082-6 | http://loinc.org | ST initial amplitude 6 ms in lead AVF | |
| 10083-4 | http://loinc.org | ST initial amplitude 6 ms in lead AVL | |
| 10084-2 | http://loinc.org | ST initial amplitude 6 ms in lead AVR | |
| 10085-9 | http://loinc.org | ST initial amplitude 6 ms in lead I | |
| 10086-7 | http://loinc.org | ST initial amplitude 6 ms in lead II | |
| 10087-5 | http://loinc.org | ST initial amplitude 6 ms in lead III | |
| 10088-3 | http://loinc.org | ST initial amplitude 6 ms in lead V1 | |
| 10089-1 | http://loinc.org | ST initial amplitude 6 ms in lead V2 | |
| 1009-0 | http://loinc.org | Deprecated Direct antiglobulin test.poly specific reagent [Presence] on Red Blood Cells | |
| 10090-9 | http://loinc.org | ST initial amplitude 6 ms in lead V3 | |
| 10091-7 | http://loinc.org | ST initial amplitude 6 ms in lead V4 | |
| 10092-5 | http://loinc.org | ST initial amplitude 6 ms in lead V5 | |
| 10093-3 | http://loinc.org | ST initial amplitude 6 ms in lead V6 | |
| 10094-1 | http://loinc.org | ST slope in lead AVF | |
| 10095-8 | http://loinc.org | ST slope in lead AVL | |
| 10096-6 | http://loinc.org | ST slope in lead AVR | |
| 10097-4 | http://loinc.org | ST slope in lead I | |
| 10098-2 | http://loinc.org | ST slope in lead II | |
| 10099-0 | http://loinc.org | ST slope in lead III | |
| 101-6 | http://loinc.org | Cefoperazone [Susceptibility] by Disk diffusion (KB) | |
| 1010-8 | http://loinc.org | Ew Ab [Presence] in Serum or Plasma from Blood product unit | |
| 10100-6 | http://loinc.org | ST slope in lead V1 | |
| 10101-4 | http://loinc.org | ST slope in lead V2 | |
| 10102-2 | http://loinc.org | ST slope in lead V3 | |
| 10103-0 | http://loinc.org | ST slope in lead V4 | |
| 10104-8 | http://loinc.org | ST slope in lead V5 | |
| 10105-5 | http://loinc.org | ST slope in lead V6 | |
| 10106-3 | http://loinc.org | ST wave end displacement in lead AVF | |
| 10107-1 | http://loinc.org | ST wave end displacement in lead AVL | |
| 10108-9 | http://loinc.org | ST wave end displacement in lead AVR | |
| 10109-7 | http://loinc.org | ST wave end displacement in lead I | |
| 1011-6 | http://loinc.org | Ew Ab [Presence] in Serum or Plasma from donor | |
| 10110-5 | http://loinc.org | ST wave end displacement in lead II | |
| 10111-3 | http://loinc.org | ST wave end displacement in lead III | |
| 10112-1 | http://loinc.org | ST wave end displacement in lead V1 | |
| 10113-9 | http://loinc.org | ST wave end displacement in lead V2 | |
| 10114-7 | http://loinc.org | ST wave end displacement in lead V3 | |
| 10115-4 | http://loinc.org | ST wave end displacement in lead V4 | |
| 10116-2 | http://loinc.org | ST wave end displacement in lead V5 | |
| 10117-0 | http://loinc.org | ST wave end displacement in lead V6 | |
| 10118-8 | http://loinc.org | ST wave mid displacement in lead AVF | |
| 10119-6 | http://loinc.org | ST wave mid displacement in lead AVL | |
| 1012-4 | http://loinc.org | Ew Ab [Presence] in Serum or Plasma | |
| 10120-4 | http://loinc.org | ST wave mid displacement in lead AVR | |
| 10121-2 | http://loinc.org | ST wave mid displacement in lead I | |
| 10122-0 | http://loinc.org | ST wave mid displacement in lead II | |
| 10123-8 | http://loinc.org | ST wave mid displacement in lead III | |
| 10124-6 | http://loinc.org | ST wave mid displacement in lead V1 | |
| 10125-3 | http://loinc.org | ST wave mid displacement in lead V2 | |
| 10126-1 | http://loinc.org | ST wave mid displacement in lead V3 | |
| 10127-9 | http://loinc.org | ST wave mid displacement in lead V4 | |
| 10128-7 | http://loinc.org | ST wave mid displacement in lead V5 | |
| 10129-5 | http://loinc.org | ST wave mid displacement in lead V6 | |
| 1013-2 | http://loinc.org | Ew Ag [Presence] on Red Blood Cells from Blood product unit | |
| 10130-3 | http://loinc.org | T' wave amplitude in lead AVF | |
| 10131-1 | http://loinc.org | T' wave amplitude in lead AVL | |
| 10132-9 | http://loinc.org | T' wave amplitude in lead AVR | |
| 10133-7 | http://loinc.org | T' wave amplitude in lead I | |
| 10134-5 | http://loinc.org | T' wave amplitude in lead II | |
| 10135-2 | http://loinc.org | T' wave amplitude in lead III | |
| 10136-0 | http://loinc.org | T' wave amplitude in lead V1 | |
| 10137-8 | http://loinc.org | T' wave amplitude in lead V2 | |
| 10138-6 | http://loinc.org | T' wave amplitude in lead V3 | |
| 10139-4 | http://loinc.org | T' wave amplitude in lead V4 | |
| 1014-0 | http://loinc.org | Ew Ag [Presence] on Red Blood Cells from donor | |
| 10140-2 | http://loinc.org | T' wave amplitude in lead V5 | |
| 10141-0 | http://loinc.org | T' wave amplitude in lead V6 | |
| 10142-8 | http://loinc.org | T wave amplitude in lead AVF | |
| 10143-6 | http://loinc.org | T wave amplitude in lead AVL | |
| 10144-4 | http://loinc.org | T wave amplitude in lead AVR | |
| 10145-1 | http://loinc.org | T wave amplitude in lead I | |
| 10146-9 | http://loinc.org | T wave amplitude in lead II | |
| 10147-7 | http://loinc.org | T wave amplitude in lead III | |
| 10148-5 | http://loinc.org | T wave amplitude in lead V1 | |
| 10149-3 | http://loinc.org | T wave amplitude in lead V2 | |
| 1015-7 | http://loinc.org | Ew Ag [Presence] on Red Blood Cells | |
| 10150-1 | http://loinc.org | T wave amplitude in lead V3 | |
| 10151-9 | http://loinc.org | T wave amplitude in lead V4 | |
| 10152-7 | http://loinc.org | T wave amplitude in lead V5 | |
| 10153-5 | http://loinc.org | T wave amplitude in lead V6 | |
| 10154-3 | http://loinc.org | Chief complaint Narrative - Reported | |
| 10155-0 | http://loinc.org | History of allergies, reported | |
| 10156-8 | http://loinc.org | History of Childhood diseases Narrative | |
| 10157-6 | http://loinc.org | History of family member diseases Narrative | |
| 10158-4 | http://loinc.org | History of Functional status Narrative | |
| 10159-2 | http://loinc.org | History of Industrial exposure Narrative | |
| 1016-5 | http://loinc.org | E Ab [Presence] in Serum or Plasma from Blood product unit | |
| 10160-0 | http://loinc.org | History of Medication use Narrative | |
| 10161-8 | http://loinc.org | History of Occupational exposure Narrative | |
| 10162-6 | http://loinc.org | History of pregnancies Narrative | |
| 10163-4 | http://loinc.org | History of pregnancies | |
| 10164-2 | http://loinc.org | History of Present illness Narrative | |
| 10165-9 | http://loinc.org | Deprecated History of psychiatric symptoms and diseases Narrative | |
| 10166-7 | http://loinc.org | History of Social function Narrative | |
| 10167-5 | http://loinc.org | History of Surgical procedures Narrative | |
| 10168-3 | http://loinc.org | History of Cardiovascular system disorders Narrative | |
| 10169-1 | http://loinc.org | History of Ear disorders Narrative | |
| 1017-3 | http://loinc.org | E Ab [Presence] in Serum or Plasma from donor | |
| 10170-9 | http://loinc.org | History of Endocrine system disorders Narrative | |
| 10171-7 | http://loinc.org | History of Eyes disorders Narrative | |
| 10172-5 | http://loinc.org | History of Hematologic system disorders Narrative | |
| 10173-3 | http://loinc.org | History of Musculoskeletal system disorders Narrative | |
| 10174-1 | http://loinc.org | History of Nose disorders Narrative | |
| 10175-8 | http://loinc.org | History of Oral cavity disorders Narrative | |
| 10176-6 | http://loinc.org | History of Reproductive system disorders Narrative | |
| 10177-4 | http://loinc.org | History of Respiratory system disorders Narrative | |
| 10178-2 | http://loinc.org | History of Skin disorders Narrative | |
| 10179-0 | http://loinc.org | History of Throat and Neck disorders Narrative | |
| 1018-1 | http://loinc.org | E Ab [Presence] in Serum or Plasma | |
| 10180-8 | http://loinc.org | History of Throat and Neck disorders | |
| 10181-6 | http://loinc.org | History of Urinary tract disorders Narrative | |
| 10182-4 | http://loinc.org | History of Travel Narrative | |
| 10183-2 | http://loinc.org | Hospital discharge medications Narrative | |
| 10184-0 | http://loinc.org | Hospital discharge physical findings Narrative | |
| 10185-7 | http://loinc.org | Hospital discharge procedures Narrative | |
| 10186-5 | http://loinc.org | Identifying information Narrative Observed | |
| 10187-3 | http://loinc.org | Review of systems Narrative - Reported | |
| 10188-1 | http://loinc.org | Review of systems overview Narrative - Reported | |
| 10189-9 | http://loinc.org | Review of systems overview - Reported | |
| 1019-9 | http://loinc.org | E Ag [Presence] on Red Blood Cells from Blood product unit | |
| 10190-7 | http://loinc.org | Mental status Narrative | |
| 10191-5 | http://loinc.org | Physical findings of Abdomen Narrative | |
| 10192-3 | http://loinc.org | Physical findings of Back Narrative | |
| 10193-1 | http://loinc.org | Physical findings of Breasts Narrative | |
| 10194-9 | http://loinc.org | Physical findings of Neurologic deep tendon reflexes Narrative | |
| 10195-6 | http://loinc.org | Physical findings of Ear Narrative | |
| 10196-4 | http://loinc.org | Physical findings of Extremities Narrative | |
| 10197-2 | http://loinc.org | Physical findings of Eye Narrative | |
| 10198-0 | http://loinc.org | Physical findings of Genitourinary tract Narrative | |
| 10199-8 | http://loinc.org | Physical findings of Head Narrative | |
| 102-4 | http://loinc.org | Cefoperazone [Susceptibility] by Serum bactericidal titer | |
| 1020-7 | http://loinc.org | E Ag [Presence] on Red Blood Cells from donor | |
| 10200-4 | http://loinc.org | Physical findings of Heart Narrative | |
| 10201-2 | http://loinc.org | Physical findings of Mouth and Throat and Teeth Narrative | |
| 10202-0 | http://loinc.org | Physical findings of Nervous system Narrative | |
| 10203-8 | http://loinc.org | Physical findings of Nose Narrative | |
| 10204-6 | http://loinc.org | Physical findings of Pelvis Narrative | |
| 10205-3 | http://loinc.org | Physical findings of Rectum Narrative | |
| 10206-1 | http://loinc.org | Physical findings of Skin Narrative | |
| 10207-9 | http://loinc.org | Physical findings of Thorax and Lungs Narrative | |
| 10208-7 | http://loinc.org | Physical findings of Vessels Narrative | |
| 10209-5 | http://loinc.org | Physical findings of Neurologic balance and Coordination Narrative | |
| 1021-5 | http://loinc.org | E Ag [Presence] on Red Blood Cells | |
| 10210-3 | http://loinc.org | Physical findings of General status Narrative | |
| 10211-1 | http://loinc.org | Physical findings of Sense of touch Narrative | |
| 10212-9 | http://loinc.org | Physical findings of Strength Narrative | |
| 10213-7 | http://loinc.org | Surgical operation note anesthesia Narrative | |
| 10214-5 | http://loinc.org | Surgical operation note anesthesia duration | |
| 10215-2 | http://loinc.org | Surgical operation note findings Narrative | |
| 10216-0 | http://loinc.org | Surgical operation note fluids Narrative | |
| 10217-8 | http://loinc.org | Surgical operation note indications [Interpretation] Narrative | |
| 10218-6 | http://loinc.org | Surgical operation note postoperative diagnosis Narrative | |
| 10219-4 | http://loinc.org | Surgical operation note preoperative diagnosis Narrative | |
| 1022-3 | http://loinc.org | Fy sup(a) Ab [Presence] in Serum or Plasma from Blood product unit | |
| 10220-2 | http://loinc.org | Surgical operation note prep time duration | |
| 10221-0 | http://loinc.org | Surgical operation note specimens taken Narrative | |
| 10222-8 | http://loinc.org | Surgical operation note surgical complications [Interpretation] Narrative | |
| 10223-6 | http://loinc.org | Surgical operation note surgical procedure Narrative | |
| 10224-4 | http://loinc.org | Hemodynamic method special circumstances | |
| 10225-1 | http://loinc.org | Cardiac measurement device Institution inventory number | |
| 10226-9 | http://loinc.org | Oxygen content in Intravascular space | |
| 10227-7 | http://loinc.org | Cardiac measurement device Vendor model number | |
| 10228-5 | http://loinc.org | Cardiac measurement device Vendor serial number | |
| 10229-3 | http://loinc.org | Hemodynamic method Type of | |
| 1023-1 | http://loinc.org | Fy sup(a) Ab [Presence] in Serum or Plasma from donor | |
| 10230-1 | http://loinc.org | Left ventricular Ejection fraction | |
| 10231-9 | http://loinc.org | Right ventricular Ejection fraction | |
| 10232-7 | http://loinc.org | Oxygen content in Aorta root | |
| 10233-5 | http://loinc.org | Oxygen content in Left atrium | |
| 10234-3 | http://loinc.org | Oxygen content in Right atrium | |
| 10235-0 | http://loinc.org | Oxygen content in High right atrium | |
| 10236-8 | http://loinc.org | Oxygen content in Low right atrium | |
| 10237-6 | http://loinc.org | Oxygen content in Mid right atrium | |
| 10238-4 | http://loinc.org | Oxygen content in Left ventricle | |
| 10239-2 | http://loinc.org | Oxygen content in Right ventricular outflow tract | |
| 1024-9 | http://loinc.org | Fy sup(a) Ab [Presence] in Serum or Plasma | |
| 10240-0 | http://loinc.org | Oxygen content in Right ventricle | |
| 10241-8 | http://loinc.org | Oxygen content in Coronary sinus | |
| 10242-6 | http://loinc.org | Oxygen content in Ductus arteriosus | |
| 10243-4 | http://loinc.org | Oxygen content in Inferior vena cava | |
| 10244-2 | http://loinc.org | Oxygen content in Left pulmonary artery | |
| 10245-9 | http://loinc.org | Oxygen content in Main pulmonary artery | |
| 10246-7 | http://loinc.org | Oxygen content in Right pulmonary artery | |
| 10247-5 | http://loinc.org | Oxygen content in Pulmonary wedge | |
| 10248-3 | http://loinc.org | Oxygen content in Superior vena cava | |
| 10249-1 | http://loinc.org | Heart rate device Institution inventory number | |
| 1025-6 | http://loinc.org | Fy sup(a) Ag [Presence] on Red Blood Cells from Blood product unit | |
| 10250-9 | http://loinc.org | Heart rate device Vendor model number | |
| 10251-7 | http://loinc.org | Heart rate device Vendor serial number | |
| 10252-5 | http://loinc.org | Biliary drain site | |
| 10253-3 | http://loinc.org | Type of Biliary drain | |
| 10254-1 | http://loinc.org | Type of Peritoneal drain | |
| 10255-8 | http://loinc.org | Type of Subarachnoid drain | |
| 10256-6 | http://loinc.org | Biliary drain Institution inventory number | |
| 10257-4 | http://loinc.org | Chest tube Institution inventory number | |
| 10258-2 | http://loinc.org | Enteral tube Institution inventory number | |
| 10259-0 | http://loinc.org | Gastrostomy tube Institution inventory number | |
| 1026-4 | http://loinc.org | Fy sup(a) Ag [Presence] on Red Blood Cells from donor | |
| 10260-8 | http://loinc.org | GI tube Institution inventory number | |
| 10261-6 | http://loinc.org | Intravascular tube Institution inventory number | |
| 10262-4 | http://loinc.org | IO tube Institution inventory number | |
| 10263-2 | http://loinc.org | Nasogastric tube Institution inventory number | |
| 10264-0 | http://loinc.org | Oral tube Institution inventory number | |
| 10265-7 | http://loinc.org | Peritoneal drain Institution inventory number | |
| 10266-5 | http://loinc.org | Peritoneal tube Institution inventory number | |
| 10267-3 | http://loinc.org | Rate control device Institution inventory number | |
| 10268-1 | http://loinc.org | Stool collection device Institution inventory number | |
| 10269-9 | http://loinc.org | Subarachnoid drain Institution inventory number | |
| 1027-2 | http://loinc.org | Fy sup(a) Ag [Presence] on Red Blood Cells | |
| 10270-7 | http://loinc.org | Synovial drain Institution inventory number | |
| 10271-5 | http://loinc.org | Tube or drain Institution inventory number | |
| 10272-3 | http://loinc.org | Upper GI tube Institution inventory number | |
| 10273-1 | http://loinc.org | Bladder irrigation tube Institution inventory number | |
| 10274-9 | http://loinc.org | Urine tube Institution inventory number | |
| 10275-6 | http://loinc.org | Wound drain device Institution inventory number | |
| 10276-4 | http://loinc.org | Peritoneal drain site | |
| 10277-2 | http://loinc.org | Stool collection site | |
| 10278-0 | http://loinc.org | Subarachnoid drain site | |
| 10279-8 | http://loinc.org | Biliary drain Vendor model number | |
| 1028-0 | http://loinc.org | Fy sup(b) Ab [Presence] in Serum or Plasma from Blood product unit | |
| 10280-6 | http://loinc.org | Chest tube Vendor model number | |
| 10281-4 | http://loinc.org | Enteral tube Vendor model number | |
| 10282-2 | http://loinc.org | Gastrostomy tube Vendor model number | |
| 10283-0 | http://loinc.org | GI tube Vendor model number | |
| 10284-8 | http://loinc.org | Intravascular tube Vendor model number | |
| 10285-5 | http://loinc.org | IO tube Vendor model number | |
| 10286-3 | http://loinc.org | Nasogastric tube Vendor model number | |
| 10287-1 | http://loinc.org | Oral tube Vendor model number | |
| 10288-9 | http://loinc.org | Peritoneal drain Vendor model number | |
| 10289-7 | http://loinc.org | Peritoneal tube Vendor model number | |
| 1029-8 | http://loinc.org | Fy sup(b) Ab [Presence] in Serum or Plasma from donor | |
| 10290-5 | http://loinc.org | Rate control device Vendor model number | |
| 10291-3 | http://loinc.org | Stool collection device Vendor model number | |
| 10292-1 | http://loinc.org | Subarachnoid drain Vendor model number | |
| 10293-9 | http://loinc.org | Synovial drain Vendor model number | |
| 10294-7 | http://loinc.org | Tube or drain Vendor model number | |
| 10295-4 | http://loinc.org | Upper GI tube Vendor model number | |
| 10296-2 | http://loinc.org | Bladder irrigation tube Vendor model number | |
| 10297-0 | http://loinc.org | Urine tube Vendor model number | |
| 10298-8 | http://loinc.org | Wound drain device Vendor model number | |
| 10299-6 | http://loinc.org | Biliary drain Vendor serial number | |
| 103-2 | http://loinc.org | Ceforanide [Susceptibility] by Minimum lethal concentration (MLC) | |
| 1030-6 | http://loinc.org | Fy sup(b) Ab [Presence] in Serum or Plasma | |
| 10300-2 | http://loinc.org | Chest tube Vendor serial number | |
| 10301-0 | http://loinc.org | Enteral tube Vendor serial number | |
| 10302-8 | http://loinc.org | Gastrostomy tube Vendor serial number | |
| 10303-6 | http://loinc.org | GI tube Vendor serial number | |
| 10304-4 | http://loinc.org | Intravascular tube Vendor serial number | |
| 10305-1 | http://loinc.org | IO tube Vendor serial number | |
| 10306-9 | http://loinc.org | Nasogastric tube Vendor serial number | |
| 10307-7 | http://loinc.org | Oral tube Vendor serial number | |
| 10308-5 | http://loinc.org | Peritoneal drain Vendor serial number | |
| 10309-3 | http://loinc.org | Peritoneal tube Vendor serial number | |
| 1031-4 | http://loinc.org | Fy sup(b) Ag [Presence] on Red Blood Cells from Blood product unit | |
| 10310-1 | http://loinc.org | Rate control device Vendor serial number | |
| 10311-9 | http://loinc.org | Stool collection device Vendor serial number | |
| 10312-7 | http://loinc.org | Subarachnoid drain Vendor serial number | |
| 10313-5 | http://loinc.org | Synovial drain Vendor serial number | |
| 10314-3 | http://loinc.org | Tube or drain Vendor serial number | |
| 10315-0 | http://loinc.org | Upper GI tube Vendor serial number | |
| 10316-8 | http://loinc.org | Bladder irrigation tube Vendor serial number | |
| 10317-6 | http://loinc.org | Urine tube Vendor serial number | |
| 10318-4 | http://loinc.org | Wound drain device Vendor serial number | |
| 10319-2 | http://loinc.org | Enema device Institution inventory number | |
| 1032-2 | http://loinc.org | Fy sup(b) Ag [Presence] on Red Blood Cells from donor | |
| 10320-0 | http://loinc.org | Enema device Vendor model number | |
| 10321-8 | http://loinc.org | Enema device Vendor serial number | |
| 10322-6 | http://loinc.org | Potassium intake 24 hour | |
| 10323-4 | http://loinc.org | Wound drain fluid [Appearance] Lower GI tract | |
| 10324-2 | http://loinc.org | Breath rate device Institution inventory number | |
| 10325-9 | http://loinc.org | Breath rate device Vendor model number | |
| 10326-7 | http://loinc.org | Breath rate device Vendor serial number | |
| 10327-5 | http://loinc.org | Eosinophils/100 leukocytes in Sputum by Manual count | |
| 10328-3 | http://loinc.org | Lymphocytes/100 leukocytes in Cerebral spinal fluid by Manual count | |
| 10329-1 | http://loinc.org | Monocytes/100 leukocytes in Cerebral spinal fluid by Manual count | |
| 1033-0 | http://loinc.org | Fy sup(b) Ag [Presence] on Red Blood Cells | |
| 10330-9 | http://loinc.org | Monocytes/100 leukocytes in Body fluid by Manual count | |
| 10331-7 | http://loinc.org | Rh [Type] in Blood | |
| 10332-5 | http://loinc.org | Cortisol [Mass/volume] in Serum or Plasma --pre 250 ug corticotropin IM | |
| 10333-3 | http://loinc.org | Appearance of Cerebral spinal fluid | |
| 10334-1 | http://loinc.org | Cancer Ag 125 [Units/volume] in Serum or Plasma | |
| 10335-8 | http://loinc.org | Color of Cerebral spinal fluid | |
| 10336-6 | http://loinc.org | Gonadotropin peptide [Mass/volume] in Urine | |
| 10337-4 | http://loinc.org | Procollagen type I [Mass/volume] in Serum | |
| 10338-2 | http://loinc.org | Barbiturates [Mass/volume] in Serum or Plasma | |
| 10339-0 | http://loinc.org | Fluoxetine+Norfluoxetine [Mass/volume] in Serum or Plasma | |
| 1034-8 | http://loinc.org | Fetal cell screen [Interpretation] in Blood | |
| 10340-8 | http://loinc.org | Molindone [Mass/volume] in Serum or Plasma | |
| 10341-6 | http://loinc.org | Norpropoxyphene [Mass/volume] in Serum or Plasma | |
| 10342-4 | http://loinc.org | Sulfamethoxazole [Mass/volume] in Serum or Plasma | |
| 10343-2 | http://loinc.org | Temazepam [Mass/volume] in Serum or Plasma | |
| 10344-0 | http://loinc.org | Tranylcypromine [Mass/volume] in Serum or Plasma | |
| 10345-7 | http://loinc.org | Trihexyphenidyl [Mass/volume] in Urine | |
| 10346-5 | http://loinc.org | Hemoglobin A [Units/volume] in Blood by Electrophoresis | |
| 10347-3 | http://loinc.org | Babesia microti identified in Blood by Light microscopy | |
| 10348-1 | http://loinc.org | Bordetella parapertussis Ab [Presence] in Serum | |
| 10349-9 | http://loinc.org | Brucella sp Ab [Units/volume] in Serum | |
| 1035-5 | http://loinc.org | Fresh frozen plasma given [Volume] | |
| 10350-7 | http://loinc.org | Herpes simplex virus IgM Ab [Titer] in Serum by Immunoassay | |
| 10351-5 | http://loinc.org | HIV 1 RNA [Units/volume] (viral load) in Serum or Plasma by Probe with amplification | |
| 10352-3 | http://loinc.org | Bacteria identified in Genital specimen by Aerobe culture | |
| 10353-1 | http://loinc.org | Bacteria identified in Nose by Aerobe culture | |
| 10354-9 | http://loinc.org | Bacteria identified in Urethra by Culture | |
| 10355-6 | http://loinc.org | Microscopic observation [Identifier] in Bone marrow by Wright Giemsa stain | |
| 10356-4 | http://loinc.org | Deprecated Microscopic observation [Identifier] in Stool by Trichrome stain | |
| 10357-2 | http://loinc.org | Microscopic observation [Identifier] in Wound by Gram stain | |
| 10358-0 | http://loinc.org | Teichoate Ab [Titer] in Serum by Immune diffusion (ID) | |
| 10359-8 | http://loinc.org | Asialoganglioside GM1 IgM Ab [Titer] in Serum | |
| 1036-3 | http://loinc.org | G Ab [Presence] in Serum or Plasma from Blood product unit | |
| 10360-6 | http://loinc.org | DNA single strand IgG Ab [Units/volume] in Serum | |
| 10361-4 | http://loinc.org | DNA single strand IgM Ab [Units/volume] in Serum | |
| 10362-2 | http://loinc.org | Endomysium IgA Ab [Presence] in Serum | |
| 10363-0 | http://loinc.org | Barbiturates [Presence] in Unspecified specimen | |
| 10364-8 | http://loinc.org | Cotinine [Mass/mass] in Hair | |
| 10365-5 | http://loinc.org | Cotinine [Mass/volume] in Serum or Plasma | |
| 10366-3 | http://loinc.org | Cotinine [Mass/volume] in Urine | |
| 10367-1 | http://loinc.org | Ethanol [Mass/volume] in Gastric fluid | |
| 10368-9 | http://loinc.org | Lead [Mass/volume] in Capillary blood | |
| 10369-7 | http://loinc.org | Opiates [Mass/mass] in Hair | |
| 1037-1 | http://loinc.org | G Ab [Presence] in Serum or Plasma from donor | |
| 10370-5 | http://loinc.org | Phencyclidine [Mass/mass] in Hair | |
| 10371-3 | http://loinc.org | Bite cells [Presence] in Blood by Light microscopy | |
| 10372-1 | http://loinc.org | Blister cells [Presence] in Blood by Light microscopy | |
| 10373-9 | http://loinc.org | Fragments [Presence] in Blood by Light microscopy | |
| 10374-7 | http://loinc.org | Helmet cells [Presence] in Blood by Light microscopy | |
| 10375-4 | http://loinc.org | Irregularly contracted cells [Presence] in Blood by Light microscopy | |
| 10376-2 | http://loinc.org | Oval macrocytes [Presence] in Blood by Light microscopy | |
| 10377-0 | http://loinc.org | Pencil cells [Presence] in Blood by Light microscopy | |
| 10378-8 | http://loinc.org | Polychromasia [Presence] in Blood by Light microscopy | |
| 10379-6 | http://loinc.org | Erythrocytes.dual population [Presence] in Blood by Light microscopy | |
| 1038-9 | http://loinc.org | G Ab [Presence] in Serum or Plasma | |
| 10380-4 | http://loinc.org | Stomatocytes [Presence] in Blood by Light microscopy | |
| 10381-2 | http://loinc.org | Target cells [Presence] in Blood by Light microscopy | |
| 10382-0 | http://loinc.org | A,B variant NOS Ag [Presence] on Red Blood Cells from Blood product unit | |
| 10383-8 | http://loinc.org | A,B variant NOS Ag [Presence] on Red Blood Cells from donor | |
| 10384-6 | http://loinc.org | A,B variant NOS Ag [Presence] on Red Blood Cells | |
| 10385-3 | http://loinc.org | Albumin concentration given | |
| 10386-1 | http://loinc.org | Albumin given [Volume] | |
| 10387-9 | http://loinc.org | Autologous erythrocytes given [Volume] | |
| 10388-7 | http://loinc.org | Autologous whole blood given [Volume] | |
| 10389-5 | http://loinc.org | Blood product.other [Type] | |
| 1039-7 | http://loinc.org | G Ag [Presence] on Red Blood Cells from Blood product unit | |
| 10390-3 | http://loinc.org | Blood product special preparation [Type] | |
| 10391-1 | http://loinc.org | Cytomegalovirus immune globulin given [Volume] | |
| 10392-9 | http://loinc.org | Cryoprecipitate given [Volume] | |
| 10393-7 | http://loinc.org | Factor IX given [Type] | |
| 10394-5 | http://loinc.org | Factor IX given [Volume] | |
| 10395-2 | http://loinc.org | Factor VIII given [Type] | |
| 10396-0 | http://loinc.org | Factor VIII given [Volume] | |
| 10397-8 | http://loinc.org | Hepatitis B immune globulin given [Volume] | |
| 10398-6 | http://loinc.org | I Ag [Presence] on Red Blood Cells from Blood product unit | |
| 10399-4 | http://loinc.org | I Ag [Presence] on Red Blood Cells from donor | |
| 104-0 | http://loinc.org | Ceforanide [Susceptibility] by Minimum inhibitory concentration (MIC) | |
| 1040-5 | http://loinc.org | G Ag [Presence] on Red Blood Cells from donor | |
| 10400-0 | http://loinc.org | I Ag [Presence] on Red Blood Cells | |
| 10401-8 | http://loinc.org | Immune serum globulin given [Type] | |
| 10402-6 | http://loinc.org | Immune serum globulin given [Volume] | |
| 10403-4 | http://loinc.org | Inject immune serum globulin [Volume] | |
| 10404-2 | http://loinc.org | Inject Rh immune globulin [Volume] | |
| 10405-9 | http://loinc.org | Inject varicella zoster virus immune globulin [Volume] | |
| 10406-7 | http://loinc.org | little i Ag [Presence] on Red Blood Cells from Blood product unit | |
| 10407-5 | http://loinc.org | little i Ag [Presence] on Red Blood Cells from donor | |
| 10408-3 | http://loinc.org | little i Ag [Presence] on Red Blood Cells | |
| 10409-1 | http://loinc.org | Pentaspan given [Volume] | |
| 1041-3 | http://loinc.org | G Ag [Presence] on Red Blood Cells | |
| 10410-9 | http://loinc.org | Plasma given [Type] | |
| 10411-7 | http://loinc.org | Plasma given [Volume] | |
| 10412-5 | http://loinc.org | Platelets given [Type] | |
| 10413-3 | http://loinc.org | Rh immune globulin given [Volume] | |
| 10414-1 | http://loinc.org | Transfuse albumin [Volume] | |
| 10415-8 | http://loinc.org | Transfuse blood exchange transfusion [Volume] | |
| 10416-6 | http://loinc.org | Transfuse blood product other [Volume] | |
| 10417-4 | http://loinc.org | Transfuse cryoprecipitate [Volume] | |
| 10418-2 | http://loinc.org | Transfuse factor IX [Volume] | |
| 10419-0 | http://loinc.org | Transfuse factor VIII [Volume] | |
| 1042-1 | http://loinc.org | H Ab [Presence] in Serum or Plasma from Blood product unit | |
| 10420-8 | http://loinc.org | Transfuse immune serum globulin [Volume] | |
| 10421-6 | http://loinc.org | Transfuse Pentaspan [Volume] | |
| 10422-4 | http://loinc.org | Transfuse plasma [Volume] | |
| 10423-2 | http://loinc.org | Transfuse platelets [Volume] | |
| 10424-0 | http://loinc.org | Transfuse erythrocytes [Volume] | |
| 10425-7 | http://loinc.org | Transfuse Rh immune globulin [Volume] | |
| 10426-5 | http://loinc.org | Transfuse whole blood [Volume] | |
| 10427-3 | http://loinc.org | Transfuse whole blood autologous [Volume] | |
| 10428-1 | http://loinc.org | Varicella zoster virus immune globulin given [Volume] | |
| 10429-9 | http://loinc.org | AE 1 Ag [Presence] in Tissue by Immune stain | |
| 1043-9 | http://loinc.org | H Ab [Presence] in Serum or Plasma from donor | |
| 10430-7 | http://loinc.org | AE 3 Ag [Presence] in Tissue by Immune stain | |
| 10431-5 | http://loinc.org | B-cell Ag [Presence] in Tissue by Immune stain | |
| 10432-3 | http://loinc.org | CD30 Ag [Presence] in Tissue by Immune stain | |
| 10433-1 | http://loinc.org | BR-2 Ag [Presence] in Tissue by Immune stain | |
| 10434-9 | http://loinc.org | Complement C3 Ag [Presence] in Tissue by Immune stain | |
| 10435-6 | http://loinc.org | C5B-9 Ag [Presence] in Tissue by Immune stain | |
| 10436-4 | http://loinc.org | CD15 Ag [Presence] in Tissue by Immune stain | |
| 10437-2 | http://loinc.org | CD16 Ag [Presence] in Tissue by Immune stain | |
| 10438-0 | http://loinc.org | CD20 Ag [Presence] in Tissue by Immune stain | |
| 10439-8 | http://loinc.org | CD3 Ag [Presence] in Tissue by Immune stain | |
| 1044-7 | http://loinc.org | H Ab [Presence] in Serum | |
| 10440-6 | http://loinc.org | Deprecated CD30 Ag [Presence] in Tissue by Immune stain | |
| 10441-4 | http://loinc.org | CD34 Ag [Presence] in Tissue by Immune stain | |
| 10442-2 | http://loinc.org | CD56 Ag [Presence] in Tissue by Immune stain | |
| 10443-0 | http://loinc.org | CD43 T-cell monocyte+myeloid cell Ag [Presence] in Tissue by Immune stain | |
| 10444-8 | http://loinc.org | CD57 Ag [Presence] in Tissue by Immune stain | |
| 10445-5 | http://loinc.org | CD11c Ag [Presence] in Tissue by Immune stain | |
| 10446-3 | http://loinc.org | Leukocyte common Ag [Presence] in Tissue by Immune stain | |
| 10447-1 | http://loinc.org | M-5 Ag [Presence] in Tissue by Immune stain | |
| 10448-9 | http://loinc.org | T-cell Ag [Presence] in Tissue by Immune stain | |
| 10449-7 | http://loinc.org | Glucose [Mass/volume] in Serum or Plasma --1 hour post meal | |
| 1045-4 | http://loinc.org | H NOS Ab [Presence] in Serum or Plasma from Blood product unit | |
| 10450-5 | http://loinc.org | Glucose [Mass/volume] in Serum or Plasma --10 hours fasting | |
| 10451-3 | http://loinc.org | Proinsulin [Moles/volume] in Serum or Plasma --12 hours fasting | |
| 10452-1 | http://loinc.org | Xylose [Mass/volume] in Serum or Plasma --1 hour post 25 g xylose PO | |
| 10453-9 | http://loinc.org | Xylose [Mass/volume] in Serum or Plasma --1 hour post dose xylose PO | |
| 10454-7 | http://loinc.org | Xylose [Mass/volume] in Serum or Plasma --2 hours post 25 g xylose PO | |
| 10455-4 | http://loinc.org | Xylose [Mass/volume] in Serum or Plasma --30 minutes post 25 g xylose PO | |
| 10456-2 | http://loinc.org | Xylose [Mass/volume] in Serum or Plasma --6 hours fasting | |
| 10457-0 | http://loinc.org | Actin Ag [Presence] in Tissue by Immune stain | |
| 10458-8 | http://loinc.org | Alkaline phosphatase.placental Ag [Presence] in Tissue by Immune stain | |
| 10459-6 | http://loinc.org | Alpha-1-Fetoprotein Ag [Presence] in Tissue by Immune stain | |
| 1046-2 | http://loinc.org | H NOS Ab [Presence] in Serum or Plasma from donor | |
| 10460-4 | http://loinc.org | Lactalbumin alpha Ag [Presence] in Tissue by Immune stain | |
| 10461-2 | http://loinc.org | Alpha-1-Antichymotrypsin Ag [Presence] in Tissue by Immune stain | |
| 10462-0 | http://loinc.org | Alpha 1 antitrypsin Ag [Presence] in Tissue by Immune stain | |
| 10463-8 | http://loinc.org | Amyloid A component Ag [Presence] in Tissue by Immune stain | |
| 10464-6 | http://loinc.org | Amyloid P component Ag [Presence] in Tissue by Immune stain | |
| 10465-3 | http://loinc.org | Amyloid.prealbumin Ag [Presence] in Tissue by Immune stain | |
| 10466-1 | http://loinc.org | Anion gap 3 in Serum or Plasma | |
| 10467-9 | http://loinc.org | Beta-2-Microglobulin amyloid Ag [Presence] in Tissue by Immune stain | |
| 10468-7 | http://loinc.org | Calcitonin Ag [Presence] in Tissue by Immune stain | |
| 10469-5 | http://loinc.org | Carcinoembryonic Ag [Presence] in Tissue by Immune stain | |
| 1047-0 | http://loinc.org | H NOS Ab [Presence] in Serum or Plasma | |
| 10470-3 | http://loinc.org | Choriogonadotropin Ag [Presence] in Tissue by Immune stain | |
| 10471-1 | http://loinc.org | Chromogranin A Ag [Presence] in Tissue by Immune stain | |
| 10472-9 | http://loinc.org | Chromogranin Ag [Presence] in Tissue by Immune stain | |
| 10473-7 | http://loinc.org | Chymotrypsin Ag [Presence] in Tissue by Immune stain | |
| 10474-5 | http://loinc.org | Collagen type 4 Ag [Presence] in Tissue by Immune stain | |
| 10475-2 | http://loinc.org | Corticotropin Ag [Presence] in Tissue by Immune stain | |
| 10476-0 | http://loinc.org | Desmin Ag [Presence] in Tissue by Immune stain | |
| 10477-8 | http://loinc.org | Enolase.neuron specific Ag [Presence] in Tissue by Immune stain | |
| 10478-6 | http://loinc.org | Eosinophil major basic protein Ag [Presence] in Tissue by Immune stain | |
| 10479-4 | http://loinc.org | CD227 Ag [Presence] in Tissue by Immune stain | |
| 1048-8 | http://loinc.org | H NOS Ag [Presence] on Red Blood Cells from Blood product unit | |
| 10480-2 | http://loinc.org | Estrogen+Progesterone receptor Ag [Presence] in Tissue by Immune stain | |
| 10481-0 | http://loinc.org | Follitropin.alpha subunit Ag [Presence] in Tissue by Immune stain | |
| 10482-8 | http://loinc.org | Follitropin.beta subunit Ag [Presence] in Tissue by Immune stain | |
| 10483-6 | http://loinc.org | Gastrin Ag [Presence] in Tissue by Immune stain | |
| 10484-4 | http://loinc.org | Glial fibrillary acidic protein Ag [Presence] in Tissue by Immune stain | |
| 10485-1 | http://loinc.org | Glucagon Ag [Presence] in Tissue by Immune stain | |
| 10486-9 | http://loinc.org | Hemoglobin Ag [Presence] in Tissue by Immune stain | |
| 10487-7 | http://loinc.org | HMB-45 Ag [Presence] in Tissue by Immune stain | |
| 10488-5 | http://loinc.org | IgA Ag [Presence] in Tissue by Immune stain | |
| 10489-3 | http://loinc.org | IgA.heavy chain Ag [Presence] in Tissue by Immune stain | |
| 1049-6 | http://loinc.org | H NOS Ag [Presence] on Red Blood Cells from donor | |
| 10490-1 | http://loinc.org | IgE Ag [Presence] in Tissue by Immune stain | |
| 10491-9 | http://loinc.org | IgG Ag [Presence] in Tissue by Immune stain | |
| 10492-7 | http://loinc.org | IgG.heavy chain Ag [Presence] in Tissue by Immune stain | |
| 10493-5 | http://loinc.org | IgM Ag [Presence] in Tissue by Immune stain | |
| 10494-3 | http://loinc.org | IgM.heavy chain Ag [Presence] in Tissue by Immune stain | |
| 10495-0 | http://loinc.org | Insulin Ag [Presence] in Tissue by Immune stain | |
| 10496-8 | http://loinc.org | Immunoglobulin light chains.kappa Ag [Presence] in Tissue by Immune stain | |
| 10497-6 | http://loinc.org | Immunoglobulin light chains.kappa amyloid Ag [Presence] in Tissue by Immune stain | |
| 10498-4 | http://loinc.org | Keratin Ag [Presence] in Tissue by Immune stain | |
| 10499-2 | http://loinc.org | Immunoglobulin light chains.lambda Ag [Presence] in Tissue by Immune stain | |
| 105-7 | http://loinc.org | Ceforanide [Susceptibility] by Disk diffusion (KB) | |
| 1050-4 | http://loinc.org | H NOS Ag [Presence] on Red Blood Cells | |
| 10500-7 | http://loinc.org | Immunoglobulin light chains.lambda amyloid Ag [Presence] in Tissue by Immune stain | |
| 10501-5 | http://loinc.org | Lutropin [Units/volume] in Serum or Plasma | |
| 10502-3 | http://loinc.org | Lutropin Ag [Presence] in Tissue by Immune stain | |
| 10503-1 | http://loinc.org | Lysozyme Ag [Presence] in Tissue by Immune stain | |
| 10504-9 | http://loinc.org | Myelin basic protein Ag [Presence] in Tissue by Immune stain | |
| 10505-6 | http://loinc.org | Myoglobin Ag [Presence] in Tissue by Immune stain | |
| 10506-4 | http://loinc.org | Peanut agglutinin Ag [Presence] in Tissue by Immune stain | |
| 10507-2 | http://loinc.org | Prolactin Ag [Presence] in Tissue by Immune stain | |
| 10508-0 | http://loinc.org | Prostate specific Ag [Presence] in Tissue by Immune stain | |
| 10509-8 | http://loinc.org | Prostatic acid phosphatase Ag [Presence] in Tissue by Immune stain | |
| 1051-2 | http://loinc.org | Hemolytic disease of newborn screen [Interpretation] in Blood | |
| 10510-6 | http://loinc.org | S-100 Ag Ag [Presence] in Tissue by Immune stain | |
| 10511-4 | http://loinc.org | Serotonin Ag [Presence] in Tissue by Immune stain | |
| 10512-2 | http://loinc.org | Somatostatin Ag [Presence] in Tissue by Immune stain | |
| 10513-0 | http://loinc.org | Somatotropin Ag [Presence] in Tissue by Immune stain | |
| 10514-8 | http://loinc.org | Synaptophysin Ag [Presence] in Tissue by Immune stain | |
| 10515-5 | http://loinc.org | Thyroglobulin Ag [Presence] in Tissue by Immune stain | |
| 10516-3 | http://loinc.org | Thyrotropin Ag [Presence] in Tissue by Immune stain | |
| 10517-1 | http://loinc.org | Trypsin Ag [Presence] in Tissue by Immune stain | |
| 10518-9 | http://loinc.org | Ulex europaeus I lectin Ag [Presence] in Tissue by Immune stain | |
| 10519-7 | http://loinc.org | Vimentin Ag [Presence] in Tissue by Immune stain | |
| 1052-0 | http://loinc.org | Deprecated I (intermediate) subtype [Presence] in Serum or Plasma from Blood product unit | |
| 10520-5 | http://loinc.org | Coagulation factor VI Ag [Presence] in Tissue by Immune stain | |
| 10521-3 | http://loinc.org | Coagulation factor VIII Ag [Presence] in Tissue by Immune stain | |
| 10522-1 | http://loinc.org | Coagulation factor XIII Ag [Presence] in Tissue by Immune stain | |
| 10523-9 | http://loinc.org | Fibrinogen Ag [Presence] in Tissue by Immune stain | |
| 10524-7 | http://loinc.org | Microscopic observation [Identifier] in Cervix by Cyto stain | |
| 10525-4 | http://loinc.org | Microscopic observation [Identifier] in Unspecified specimen by Cyto stain | |
| 10526-2 | http://loinc.org | Microscopic observation [Identifier] in Sputum by Cyto stain | |
| 10527-0 | http://loinc.org | Microscopic observation [Identifier] in Tissue by Cyto stain | |
| 10528-8 | http://loinc.org | Acetophenazine [Mass/volume] in Serum or Plasma | |
| 10529-6 | http://loinc.org | Amoxapine metabolite [Mass/volume] in Serum or Plasma | |
| 1053-8 | http://loinc.org | Deprecated I (intermediate) subtype [Presence] in serum or plasma from donor | |
| 10530-4 | http://loinc.org | Aprobarbital [Mass/volume] in Serum or Plasma | |
| 10531-2 | http://loinc.org | Bretylium [Mass/volume] in Serum or Plasma | |
| 10532-0 | http://loinc.org | Deprecated Desethylamiodarone [Mass/volume] in Serum or Plasma | |
| 10533-8 | http://loinc.org | Propoxyphene+Acetaminophen [Mass/volume] in Serum or Plasma | |
| 10534-6 | http://loinc.org | Diazoxide [Mass/volume] in Serum or Plasma | |
| 10535-3 | http://loinc.org | Digoxin [Mass/volume] in Serum or Plasma | |
| 10536-1 | http://loinc.org | Dipyridamole [Mass/volume] in Serum or Plasma | |
| 10537-9 | http://loinc.org | Deprecated Doxepin+Nordoxepin [Mass/volume] in Serum or Plasma | |
| 10538-7 | http://loinc.org | Deprecated Fluoxetine+Norfluoxetine [Mass/volume] in Serum or Plasma | |
| 10539-5 | http://loinc.org | Glipizide [Mass/volume] in Serum or Plasma | |
| 1054-6 | http://loinc.org | Deprecated I (intermediate) subtype [Presence] in srum | |
| 10540-3 | http://loinc.org | Glyburide [Mass/volume] in Serum or Plasma | |
| 10541-1 | http://loinc.org | Mepivacaine [Mass/volume] in Serum or Plasma | |
| 10542-9 | http://loinc.org | Metharbital [Mass/volume] in Serum or Plasma | |
| 10543-7 | http://loinc.org | Methsuximide+Normethsuximide [Mass/volume] in Serum or Plasma | |
| 10544-5 | http://loinc.org | Normeperidine [Presence] in Serum or Plasma | |
| 10545-2 | http://loinc.org | Normephenytoin [Mass/volume] in Serum or Plasma | |
| 10546-0 | http://loinc.org | Normethsuximide [Mass/volume] in Serum or Plasma | |
| 10547-8 | http://loinc.org | Primidone+Phenobarbital [Mass/volume] in Serum or Plasma | |
| 10548-6 | http://loinc.org | Phenytoin Free/Phenytoin.total in Serum or Plasma | |
| 10549-4 | http://loinc.org | Pirmenol [Mass/volume] in Serum or Plasma | |
| 1055-3 | http://loinc.org | Deprecated I (intermediate) subtype [Presence] on Red Blood Cells from Blood product unit | |
| 10550-2 | http://loinc.org | Deprecated Temazepam [Mass/volume] in Serum or Plasma | |
| 10551-0 | http://loinc.org | Triamterene [Mass/volume] in Serum or Plasma | |
| 10552-8 | http://loinc.org | Tricyclic antidepressants [Mass/volume] in Serum or Plasma | |
| 10553-6 | http://loinc.org | Prostatic acid phosphatase [Enzymatic activity/volume] in Genital fluid | |
| 10554-4 | http://loinc.org | Deprecated Prostatic acid phosphatase [Enzymatic activity/volume] in Seminal plasma | |
| 10555-1 | http://loinc.org | Acrosin [Entitic Catalytic Activity] in Spermatozoa | |
| 10556-9 | http://loinc.org | Deprecated Adenosine triphosphatase [Enzymatic activity/volume] in Seminal plasma | |
| 10557-7 | http://loinc.org | Adenosine triphosphate [Moles/volume] in Semen | |
| 10558-5 | http://loinc.org | Albumin [Moles/volume] in Semen | |
| 10559-3 | http://loinc.org | Deprecated Calcium [Molecules/volume] in Semen | |
| 1056-1 | http://loinc.org | Deprecated I (intermediate) subtype [Presence] on Red Blood Cells from donor | |
| 10560-1 | http://loinc.org | Carcinoembryonic Ag [Units/volume] in Semen | |
| 10561-9 | http://loinc.org | Carnitine [Moles/volume] in Semen | |
| 10562-7 | http://loinc.org | Cells [#/volume] in Cervical mucus | |
| 10563-5 | http://loinc.org | Cells other than spermatozoa [#/volume] in Semen | |
| 10564-3 | http://loinc.org | Cervical mucus [Volume] | |
| 10565-0 | http://loinc.org | Choriogonadotropin [Units/volume] in Semen | |
| 10566-8 | http://loinc.org | Deprecated Choriogonadotropin [Molecules/volume] in Semen | |
| 10567-6 | http://loinc.org | Citrate [Moles/volume] in Semen | |
| 10568-4 | http://loinc.org | Clarity of Semen | |
| 10569-2 | http://loinc.org | Color of Semen | |
| 1057-9 | http://loinc.org | Deprecated I (intermediate) subtype [Presence] on Red Blood Cells | |
| 10570-0 | http://loinc.org | Consistency of Cervical mucus | |
| 10571-8 | http://loinc.org | Deprecated Consistency of Semen | |
| 10572-6 | http://loinc.org | Deprecated Duration^post ejaculation | |
| 10573-4 | http://loinc.org | Ferning [Type] in Cervical mucus | |
| 10574-2 | http://loinc.org | Fructose [Moles/volume] in Semen | |
| 10575-9 | http://loinc.org | Deprecated Gamma glutamyl transferase [Enzymatic activity/volume] in Semen | |
| 10576-7 | http://loinc.org | Germ cells.immature [#/volume] in Semen | |
| 10577-5 | http://loinc.org | Glucosidase [Enzymatic activity/volume] in Seminal plasma | |
| 10578-3 | http://loinc.org | Glycerophosphocholine [Moles/volume] in Seminal plasma | |
| 10579-1 | http://loinc.org | Leukocytes [#/volume] in Semen | |
| 1058-7 | http://loinc.org | I Ab [Presence] in Serum or Plasma from Blood product unit | |
| 10580-9 | http://loinc.org | Liquefaction [Time] in Semen | |
| 10581-7 | http://loinc.org | Deprecated Number of entities [#] in Spermatozoa | |
| 10582-5 | http://loinc.org | pH of Cervical mucus | |
| 10583-3 | http://loinc.org | Prostaglandin F1 alpha [Moles/volume] in Semen | |
| 10584-1 | http://loinc.org | Deprecated Protein [Mass/volume] in Semen | |
| 10585-8 | http://loinc.org | Round cells [#/volume] in Semen | |
| 10586-6 | http://loinc.org | Deprecated Volume of Semen | |
| 10587-4 | http://loinc.org | Sexual abstinence duration | |
| 10588-2 | http://loinc.org | Spermatogonia [#/volume] in Semen | |
| 10589-0 | http://loinc.org | Spermatids [#/volume] in Semen by Streptoavidin-biotin method (SAB) | |
| 1059-5 | http://loinc.org | I Ab [Presence] in Serum or Plasma from donor | |
| 10590-8 | http://loinc.org | Spermatids [#/volume] in Semen by Sertoli cell barrier method (SCB) | |
| 10591-6 | http://loinc.org | Primary Spermatocytes [#/volume] in Semen | |
| 10592-4 | http://loinc.org | Secondary Spermatocytes [#/volume] in Semen | |
| 10593-2 | http://loinc.org | Spermatozoa Pyriform Head/100 spermatozoa in Semen | |
| 10594-0 | http://loinc.org | Spermatozoa Tapering Head/100 spermatozoa in Semen | |
| 10595-7 | http://loinc.org | Deprecated Spermatozoa [#/volume] in Semen | |
| 10596-5 | http://loinc.org | Deprecated Spermatozoa Ab in cervical mucosa | |
| 10597-3 | http://loinc.org | Deprecated Spermatozoa Ab in semen | |
| 10598-1 | http://loinc.org | Deprecated Spermatozoa Ab in serum | |
| 10599-9 | http://loinc.org | Spermatozoa penetration [Presence] in Seminal fluid and Cervical mucosa by Kremer test | |
| 106-5 | http://loinc.org | Ceforanide [Susceptibility] by Serum bactericidal titer | |
| 1060-3 | http://loinc.org | I Ab [Presence] in Serum or Plasma | |
| 10600-5 | http://loinc.org | Spermatozoa penetration [Presence] in Seminal fluid and Cervical mucosa | |
| 10601-3 | http://loinc.org | Spermatozoa penetration [Presence] in Seminal fluid and Cervical mucosa --post coitus | |
| 10602-1 | http://loinc.org | Spermatozoa Abnormal Head/100 spermatozoa in Semen | |
| 10603-9 | http://loinc.org | Spermatozoa Abnormal Midpiece/100 spermatozoa in Semen | |
| 10604-7 | http://loinc.org | Spermatozoa Abnormal Tail/100 spermatozoa in Semen | |
| 10605-4 | http://loinc.org | Spermatozoa Agglutinated/100 spermatozoa in Semen | |
| 10606-2 | http://loinc.org | Spermatozoa Amorphous Head/100 spermatozoa in Semen | |
| 10607-0 | http://loinc.org | Spermatozoa Coiled Tail/100 spermatozoa in Semen | |
| 10608-8 | http://loinc.org | Spermatozoa Cytoplasmic Droplet/100 spermatozoa in Semen | |
| 10609-6 | http://loinc.org | Spermatozoa Duplicate Head/100 spermatozoa in Semen | |
| 1061-1 | http://loinc.org | I NOS Ab [Presence] in Serum or Plasma from Blood product unit | |
| 10610-4 | http://loinc.org | Spermatozoa Duplicate Tail/100 spermatozoa in Semen | |
| 10611-2 | http://loinc.org | Spermatozoa Immotile/100 spermatozoa in Semen | |
| 10612-0 | http://loinc.org | Spermatozoa Large Oval Head/100 spermatozoa in Semen | |
| 10613-8 | http://loinc.org | Spermatozoa Viable/100 spermatozoa in Semen | |
| 10614-6 | http://loinc.org | Spermatozoa Motile w IgA/100 spermatozoa in Semen by Immunobead | |
| 10615-3 | http://loinc.org | Spermatozoa Motile w IgA/100 spermatozoa in Semen by Mixed antiglobulin reaction | |
| 10616-1 | http://loinc.org | Spermatozoa Motile w IgG/100 spermatozoa in Semen by Immunobead | |
| 10617-9 | http://loinc.org | Spermatozoa Motile w IgG/100 spermatozoa in Semen by Mixed antiglobulin reaction | |
| 10618-7 | http://loinc.org | Spermatozoa Motile w IgM/100 spermatozoa in Semen by Immunobead | |
| 10619-5 | http://loinc.org | Spermatozoa Motile w IgM/100 spermatozoa in Semen by Mixed antiglobulin reaction | |
| 1062-9 | http://loinc.org | I NOS Ab [Presence] in Serum or Plasma from donor | |
| 10620-3 | http://loinc.org | Spermatozoa Nonprogressive/100 spermatozoa in Semen | |
| 10621-1 | http://loinc.org | Spermatozoa Normal Head/100 spermatozoa in Semen | |
| 10622-9 | http://loinc.org | Spermatozoa Normal/100 spermatozoa in Semen | |
| 10623-7 | http://loinc.org | Spermatozoa Pin Head/100 spermatozoa in Semen | |
| 10624-5 | http://loinc.org | Spermatozoa Rapid/100 spermatozoa in Semen | |
| 10625-2 | http://loinc.org | Spermatozoa Round Head/100 spermatozoa in Semen | |
| 10626-0 | http://loinc.org | Spermatozoa Slow/100 spermatozoa in Semen | |
| 10627-8 | http://loinc.org | Spermatozoa Small Oval Head/100 spermatozoa in Semen | |
| 10628-6 | http://loinc.org | Spermatozoa Tail Swelling/100 spermatozoa in Semen | |
| 10629-4 | http://loinc.org | Spermatozoa Vacuolated Head/100 spermatozoa in Semen | |
| 1063-7 | http://loinc.org | I NOS Ab [Presence] in Serum or Plasma | |
| 10630-2 | http://loinc.org | Spinnbarkeit [Length] in Cervical mucus | |
| 10631-0 | http://loinc.org | Testosterone [Moles/volume] in Semen | |
| 10632-8 | http://loinc.org | Time until next menstrual period | |
| 10633-6 | http://loinc.org | Zinc [Moles/volume] in Semen | |
| 10634-4 | http://loinc.org | Complement C1 esterase inhibitor.functional/Complement C1 esterase inhibitor.total in Serum or Plasma | |
| 10635-1 | http://loinc.org | Acanthamoeba sp identified in Eye by Organism specific culture | |
| 10636-9 | http://loinc.org | Acanthamoeba sp identified in Eye by Wet preparation | |
| 10637-7 | http://loinc.org | Microscopic observation [Identifier] in Tissue by Night blue stain | |
| 10638-5 | http://loinc.org | Thermophilic Actinomycetes colony count [#/volume] in Unspecified specimen by Organism specific culture | |
| 10639-3 | http://loinc.org | Thermophilic Actinomycetes identified in Unspecified specimen by Organism specific culture | |
| 1064-5 | http://loinc.org | I NOS Ag [Presence] on Red Blood Cells from Blood product unit | |
| 10640-1 | http://loinc.org | Deprecated Adenovirus 40+41 [Identifier] in Stool by Electron microscopy | |
| 10641-9 | http://loinc.org | Amoeba identified in Aspirate by Immune stain | |
| 10642-7 | http://loinc.org | Amoeba identified in Aspirate by Wet preparation | |
| 10643-5 | http://loinc.org | Amoeba identified in Stool by Organism specific culture | |
| 10644-3 | http://loinc.org | Arthropod identified in Unspecified specimen | |
| 10645-0 | http://loinc.org | Aspergillus fumigatus Ag [Presence] in Tissue by Immunofluorescence | |
| 10646-8 | http://loinc.org | Astrovirus [Identifier] in Stool by Electron microscopy | |
| 10647-6 | http://loinc.org | Babesia sp identified in Blood by Thick film | |
| 10648-4 | http://loinc.org | Babesia sp identified in Blood by Thin film | |
| 10649-2 | http://loinc.org | Calicivirus [Identifier] in Stool by Electron microscopy | |
| 1065-2 | http://loinc.org | I NOS Ag [Presence] on Red Blood Cells from donor | |
| 10650-0 | http://loinc.org | Candida sp DNA [Presence] in Blood by Probe with amplification | |
| 10651-8 | http://loinc.org | Chlamydophila pneumoniae Ag [Presence] in Sputum or Bronchial |
®© HL7.org 2011+. FHIR Release 3 (STU; v3.0.2-11200) generated on Thurs, Oct 24, 2019 11:53+1100. QA Page
Links: Search |
Version History |
Table of Contents |
Credits |
Compare to DSTU2 |
|
Propose a change